1
|
Magavern EF, Kapil V, Saxena M, Gupta A, Caulfield MJ. Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy. Arterioscler Thromb Vasc Biol 2024. [PMID: 38385287 DOI: 10.1161/atvbaha.123.319220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2024]
Abstract
Hypertension is a prevalent public health problem, contributing to >10 million deaths annually. Though multiple therapeutics exist, many patients suffer from treatment-resistant hypertension or try several medications before achieving blood pressure control. Genomic advances offer mechanistic understanding of blood pressure variability, therapeutic targets, therapeutic response, and promise a stratified approach to treatment of primary hypertension. Cyclic guanosine monophosphate augmentation, aldosterone synthase inhibitors, and angiotensinogen blockade with silencing RNA and antisense therapies are among the promising novel approaches. Pharmacogenomic studies have also been done to explore the genetic bases underpinning interindividual variability in response to existing therapeutics. A polygenic approach using risk scores is likely to be the next frontier in stratifying responses to existing therapeutics.
Collapse
Affiliation(s)
- Emma F Magavern
- William Harvey Research Institute, Queen Mary University of London
| | - Vikas Kapil
- William Harvey Research Institute, Queen Mary University of London
| | - Manish Saxena
- William Harvey Research Institute, Queen Mary University of London
| | - Ajay Gupta
- William Harvey Research Institute, Queen Mary University of London
| | - Mark J Caulfield
- William Harvey Research Institute, Queen Mary University of London
| |
Collapse
|
2
|
Maniero C, Ng SM, Collett G, Godec T, Siddiqui I, Antoniou S, Kumar A, Janmohamed A, Nair S, Kotecha A, Khan R, Khanji MY, Kapil V, Gupta J, Gupta AK. Differential impact of COVID-19 on mental health and burnout. Occup Med (Lond) 2024; 74:45-52. [PMID: 37040624 PMCID: PMC10875923 DOI: 10.1093/occmed/kqad011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/13/2023] Open
Abstract
BACKGROUND There may be differential impact of the COVID-19 pandemic on mental health and burnout rates of healthcare professionals (HCPs) performing different roles. AIMS To examine mental health and burnout rates, and possible drivers for any disparities between professional roles. METHODS In this cohort study, online surveys were distributed to HCPs in July-September 2020 (baseline) and re-sent 4 months later (follow-up; December 2020) assessing for probable major depressive disorder (MDD), generalized anxiety disorder (GAD), insomnia, mental well-being and burnout (emotional exhaustion and depersonalization). Separate logistic regression models (at both phases) compared the risk of outcomes between roles: healthcare assistants (HCAs), nurses and midwives (nurses), allied health professionals (AHPs) and doctors (reference group). Separate linear regression models were also developed relating the change in scores to professional role. RESULTS At baseline (n = 1537), nurses had a 1.9-fold and 2.5-fold increased risk of MDD and insomnia, respectively. AHPs had a 1.7-fold and 1.4-fold increased risk of MDD and emotional exhaustion, respectively. At follow-up (n = 736), the disproportionate risk between doctors and others worsened: nurses and HCAs were at 3.7-fold and 3.6-fold increased risk of insomnia, respectively. Nurses also had a significantly increased risk of MDD, GAD, poor mental well-being and burnout. Nurses also had significantly worsened anxiety, mental well-being and burnout scores over time, relative to doctors. CONCLUSIONS Nurses and AHPs had excess risk of adverse mental health and burnout during the pandemic, and this difference worsened over time (in nurses especially). Our findings support adoption of targeted strategies accounting for different HCP roles.
Collapse
Affiliation(s)
- C Maniero
- Barts Heart Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UK
- William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK
| | - S M Ng
- Barts Heart Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UK
| | - G Collett
- William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK
| | - T Godec
- William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK
| | - I Siddiqui
- Wellbeing Hub, Newham Training Hub, London E15 1HP, UK
- Northeast London CCG, London E15 1DA, UK
- Woodgrange Medical Practice, London E7 0QH, UK
| | - S Antoniou
- Barts Heart Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UK
| | - A Kumar
- Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan WN1 1XX, UK
| | - A Janmohamed
- St George’s University Hospitals NHS Foundation Trust, London SW17 0QT, UK
| | - S Nair
- Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Wales LL18 5UJ, UK
| | - A Kotecha
- Royal Devon and Exeter Hospital, Exeter, Devon EX2 5DW, UK
| | - R Khan
- The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, UK
| | - M Y Khanji
- Barts Heart Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UK
- William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK
- UCLPartners, London W1T 7HA, UK
- Newham University Hospital, Barts Health NHS Trust, London E13 8SL, UK
| | - V Kapil
- Barts Heart Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UK
- William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK
- The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, UK
| | - J Gupta
- South West London and St George’s Mental Health NHS Trust, London SW17 0YF, UK
| | - A K Gupta
- Barts Heart Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UK
- William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK
- The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, UK
| |
Collapse
|
3
|
Lewis P, George J, Kapil V, Poulter NR, Partridge S, Goodman J, Faconti L, McCormack T, Wilkinson IB. Adult hypertension referral pathway and therapeutic management: British and Irish Hypertension Society position statement. J Hum Hypertens 2024; 38:3-7. [PMID: 38196000 PMCID: PMC10803252 DOI: 10.1038/s41371-023-00882-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 11/23/2023] [Accepted: 11/30/2023] [Indexed: 01/11/2024]
Abstract
In the UK, most adults with hypertension are managed in Primary Care. Referrals to Secondary Care Hypertension Specialists are targeted to patients in whom further investigations are likely to change management decisions. In this position statement the British and Irish Hypertension Society provide clinicians with a framework for referring patients to Hypertension Specialists. Additional therapeutic advice is provided to optimise patient management whilst awaiting specialist review. Our aim is to ensure that referral criteria to Hypertension Specialists are consistent across the UK and Ireland to ensure equitable access for all patients.
Collapse
Affiliation(s)
- Philip Lewis
- Stockport NHS Foundation Trust, Stockport, SK2 7JE, UK
| | - Jacob George
- Division of Molecular & Clinical Medicine, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY, UK
| | - Vikas Kapil
- William Harvey Research Institute, Centre for Cardiovascular Medicine and Devices, Queen Mary University London, London, EC1M 6BQ, UK
| | - Neil R Poulter
- Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, W12 7RH, UK
| | - Sarah Partridge
- Department of Primary Care and Public Health, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PH, UK.
| | - James Goodman
- Department of Clinical Pharmacology and Therapeutics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
| | - Luca Faconti
- King's College London British Heart Foundation Centre, Department of Clinical Pharmacology, 4th Floor, North Wing, St. Thomas' Hospital, Westminster Bridge, London, SE17EH, UK
| | - Terry McCormack
- Institute of Clinical and Applied Health Research, Hull York Medical School, Hull, HU6 7RX, UK
| | - Ian B Wilkinson
- Division of Experimental Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK
| |
Collapse
|
4
|
Faconti L, Kulkarni S, Delles C, Kapil V, Lewis P, Glover M, MacDonald TM, Wilkinson IB. Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society. J Hum Hypertens 2024; 38:8-18. [PMID: 37964158 PMCID: PMC10803267 DOI: 10.1038/s41371-023-00875-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 10/03/2023] [Accepted: 10/30/2023] [Indexed: 11/16/2023]
Abstract
Alongside the lack of homogeneity among international guidelines and consensus documents on primary hyperaldosteronism, the National UK guidelines on hypertension do not provide extensive recommendations regarding the diagnosis and management of this condition. Local guidelines vary from area to area, and this is reflected in the current clinical practice in the UK. In an attempt to provide support to the clinicians involved in the screening of subjects with hypertension and clinical management of suspected cases of primary hyperaldosteronism the following document has been prepared on the behalf of the BIHS Guidelines and Information Service Standing Committee. Through remote video conferences, the authors of this document reviewed an initial draft which was then circulated among the BIHS Executive members for feedback. A survey among members of the BIHS was carried out in 2022 to assess screening strategies and clinical management of primary hyperaldosteronism in the different regions of the UK. Feedback and results of the survey were then discussed and incorporated in the final document which was approved by the panel after consensus was achieved considering critical review of existing literature and expert opinions. Grading of recommendations was not performed in light of the limited available data from properly designed randomized controlled trials.
Collapse
Affiliation(s)
- Luca Faconti
- King's College London British Heart Foundation Centre, Department of Clinical Pharmacology, 4th Floor, North Wing, St. Thomas' Hospital, Westminster Bridge, London, SE17EH, UK.
| | - Spoorthy Kulkarni
- Cambridge University hospitals NHS foundation trust, Cambridge United Kingdom (S.K.), Cambridge, UK
| | - Christian Delles
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, G12 8TA, UK
| | - Vikas Kapil
- William Harvey Research Institute, Centre for Cardiovascular Medicine and Devices, Queen Mary University London, London, EC1M 6BQ, UK
- Barts BP Centre of Excellence, Barts Heart Centre, London, EC1A 7BE, UK
| | - Philip Lewis
- Department of Cardiology, Stockport NHS Foundation Trust, Stockport, UK
| | - Mark Glover
- Deceased, formerly Division of Therapeutics and Molecular Medicine, School of Medicine, University of Nottingham, Nottingham, UK
| | - Thomas M MacDonald
- Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK
| | - Ian B Wilkinson
- Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK
| |
Collapse
|
5
|
Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ, Sharman JE, Vogt L, Burrell LM, Korostovtseva L, Zec M, Patil M, Schultz MG, Wallen MP, Renna NF, Islam SMS, Hiremath S, Gyeltshen T, Chia YC, Gupta A, Schutte AE, Klein B, Borghi C, Browning CJ, Czesnikiewicz-Guzik M, Lee HY, Itoh H, Miura K, Brunström M, Campbell NR, Akinnibossun OA, Veerabhadrappa P, Wainford RD, Kruger R, Thomas SA, Komori T, Ralapanawa U, Cornelissen VA, Kapil V, Li Y, Zhang Y, Jafar TH, Khan N, Williams B, Stergiou G, Tomaszewski M. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens 2024; 42:23-49. [PMID: 37712135 PMCID: PMC10713007 DOI: 10.1097/hjh.0000000000003563] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 08/12/2023] [Accepted: 08/22/2023] [Indexed: 09/16/2023]
Abstract
Hypertension, defined as persistently elevated systolic blood pressure (SBP) >140 mmHg and/or diastolic blood pressure (DBP) at least 90 mmHg (International Society of Hypertension guidelines), affects over 1.5 billion people worldwide. Hypertension is associated with increased risk of cardiovascular disease (CVD) events (e.g. coronary heart disease, heart failure and stroke) and death. An international panel of experts convened by the International Society of Hypertension College of Experts compiled lifestyle management recommendations as first-line strategy to prevent and control hypertension in adulthood. We also recommend that lifestyle changes be continued even when blood pressure-lowering medications are prescribed. Specific recommendations based on literature evidence are summarized with advice to start these measures early in life, including maintaining a healthy body weight, increased levels of different types of physical activity, healthy eating and drinking, avoidance and cessation of smoking and alcohol use, management of stress and sleep levels. We also discuss the relevance of specific approaches including consumption of sodium, potassium, sugar, fibre, coffee, tea, intermittent fasting as well as integrated strategies to implement these recommendations using, for example, behaviour change-related technologies and digital tools.
Collapse
Affiliation(s)
- Fadi J. Charchar
- Health Innovation and Transformation Centre, Federation University Australia, Ballarat, Australia
- Department of Physiology, University of Melbourne, Melbourne, Australia
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
| | - Priscilla R. Prestes
- Health Innovation and Transformation Centre, Federation University Australia, Ballarat, Australia
| | - Charlotte Mills
- Department of Food and Nutritional Sciences, University of Reading, Reading, UK
| | - Siew Mooi Ching
- Department of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang
- Department of Medical Sciences, School of Medical and Live Sciences, Sunway University, Bandar Sunway, Selangor, Malaysia
| | - Dinesh Neupane
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA
| | - Francine Z. Marques
- Hypertension Research Laboratory, School of Biological Sciences, Monash University
- Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne
| | - James E. Sharman
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
| | - Liffert Vogt
- Department of Internal Medicine, Section Nephrology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Microcirculation, Amsterdam, The Netherlands
| | - Louise M. Burrell
- Department of Medicine, University of Melbourne, Austin Health, Melbourne, Australia
| | - Lyudmila Korostovtseva
- Department of Hypertension, Almazov National Medical Research Centre, St Petersburg, Russia
| | - Manja Zec
- School of Nutritional Sciences and Wellness, University of Arizona, Tucson, USA
- Colorado Program for Musculoskeletal Research, Department of Orthopedics, University of Colorado Anschutz Medical Campus, Aurora, USA
| | - Mansi Patil
- Department of Nutrition and Dietetics, Asha Kiran JHC Hospital, Chinchwad
- Hypertension and Nutrition, Core Group of IAPEN India, India
| | - Martin G. Schultz
- Department of Internal Medicine, Section Nephrology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Microcirculation, Amsterdam, The Netherlands
| | | | - Nicolás F. Renna
- Unit of Hypertension, Hospital Español de Mendoza, School of Medicine, National University of Cuyo, IMBECU-CONICET, Mendoza, Argentina
| | | | - Swapnil Hiremath
- Department of Medicine, University of Ottawa and the Ottawa Hospital, Ottawa, Canada
| | - Tshewang Gyeltshen
- Graduate School of Public Health, St. Luke's International University, Tokyo, Japan
| | - Yook-Chin Chia
- Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, Selangor
- Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Abhinav Gupta
- Department of Medicine, Acharya Shri Chander College of Medical Sciences and Hospital, Jammu, India
| | - Aletta E. Schutte
- School of Population Health, University of New South Wales, The George Institute for Global Health, Sydney, New South Wales, Australia
- Hypertension in Africa Research Team, SAMRC Unit for Hypertension and Cardiovascular Disease, North-West University
- SAMRC Developmental Pathways for Health Research Unit, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa
| | - Britt Klein
- Health Innovation and Transformation Centre, Federation University Australia, Ballarat, Australia
| | - Claudio Borghi
- Department of Medical and Surgical Sciences, Faculty of Medicine, University of Bologna, Bologna, Italy
| | - Colette J. Browning
- Health Innovation and Transformation Centre, Federation University Australia, Ballarat, Australia
| | - Marta Czesnikiewicz-Guzik
- School of Medicine, Dentistry and Nursing-Dental School, University of Glasgow, UK
- Department of Periodontology, Prophylaxis and Oral Medicine; Jagiellonian University, Krakow, Poland
| | - Hae-Young Lee
- Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
| | - Hiroshi Itoh
- Department of Internal Medicine (Nephrology, Endocrinology and Metabolism), Keio University, Tokyo
| | - Katsuyuki Miura
- NCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan
| | - Mattias Brunström
- Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
| | - Norm R.C. Campbell
- Libin Cardiovascular Institute, Department of Medicine, University of Calgary, Calgary, Canada
| | | | - Praveen Veerabhadrappa
- Kinesiology, Division of Science, The Pennsylvania State University, Reading, Pennsylvania
| | - Richard D. Wainford
- Department of Pharmacology and Experimental Therapeutics, The Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston
- Division of Cardiology, Emory University, Atlanta, USA
| | - Ruan Kruger
- Hypertension in Africa Research Team (HART), North-West University, Potchefstroom
- MRC Research Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa
| | - Shane A. Thomas
- Health Innovation and Transformation Centre, Federation University Australia, Ballarat, Australia
| | - Takahiro Komori
- Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan
| | - Udaya Ralapanawa
- Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka
| | | | - Vikas Kapil
- William Harvey Research Institute, Centre for Cardiovascular Medicine and Devices, NIHR Barts Biomedical Research Centre, BRC, Faculty of Medicine and Dentistry, Queen Mary University London
- Barts BP Centre of Excellence, Barts Heart Centre, Barts Health NHS Trust, London, UK
| | - Yan Li
- Department of Cardiovascular Medicine, Shanghai Institute of Hypertension, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
| | - Yuqing Zhang
- Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Chinese Hypertension League, Beijing, China
| | - Tazeen H. Jafar
- Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore
- Duke Global Health Institute, Duke University, Durham, North Carolina, USA
| | - Nadia Khan
- Department of Medicine, University of British Columbia, Vancouver, Canada
| | - Bryan Williams
- University College London (UCL), Institute of Cardiovascular Science, National Institute for Health Research (NIHR), UCL Hospitals Biomedical Research Centre, London, UK
| | - George Stergiou
- Hypertension Centre STRIDE-7, School of Medicine, Third Department of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Maciej Tomaszewski
- Division of Cardiovascular Sciences, Faculty of Medicine, Biology and Health, University of Manchester
- Manchester Academic Health Science Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK
| |
Collapse
|
6
|
Lobo MD, Rull G, Saxena M, Kapil V. Selecting patients for interventional procedures to treat hypertension. Blood Press 2023; 32:2248276. [PMID: 37665430 DOI: 10.1080/08037051.2023.2248276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 08/08/2023] [Accepted: 08/10/2023] [Indexed: 09/05/2023]
Abstract
Purpose: Interventional approaches to treat hypertension are an emerging option that may be suitable for patients whose BP control cannot be achieved with lifestyle and/or pharmacotherapy and possibly for those who do not wish to take drug therapy.Materials and Methods: Interventional strategies include renal denervation with radiofrequency, ultrasound and alcohol-mediated platforms as well as baroreflex activation therapy and cardiac neuromodulation therapy. Presently renal denervation is the most advanced of the therapeutic options and is currently being commercialised in the EU.Results: It is apparent that RDN is effective in both unmedicated patients and patients with more severe hypertension including those with resistant hypertension.Conclusion: However, at present there is no evidence for the use of RDN in patients with secondary forms of hypertension and thus evaluation to rule these out is necessary before proceeding with a procedure. Furthermore, there are numerous pitfalls in the diagnosis and management of secondary hypertension which need to be taken into consideration. Finally, prior to performing an intervention it is appropriate to document presence/absence of hypertension-mediated organ damage.
Collapse
Affiliation(s)
- Melvin D Lobo
- William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK
| | - Gurvinder Rull
- William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK
| | - Manish Saxena
- William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK
| | - Vikas Kapil
- William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK
| |
Collapse
|
7
|
Kulkarni S, Glover M, Kapil V, Abrams SML, Partridge S, McCormack T, Sever P, Delles C, Wilkinson IB. Management of hypertensive crisis: British and Irish Hypertension Society Position document. J Hum Hypertens 2023; 37:863-879. [PMID: 36418425 PMCID: PMC10539169 DOI: 10.1038/s41371-022-00776-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 10/12/2022] [Accepted: 11/03/2022] [Indexed: 11/24/2022]
Abstract
Patients with hypertensive emergencies, malignant hypertension and acute severe hypertension are managed heterogeneously in clinical practice. Initiating anti-hypertensive therapy and setting BP goal in acute settings requires important considerations which differ slightly across various diagnoses and clinical contexts. This position paper by British and Irish Hypertension Society, aims to provide clinicians a framework for diagnosing, evaluating, and managing patients with hypertensive crisis, based on the critical appraisal of available evidence and expert opinion.
Collapse
Affiliation(s)
- Spoorthy Kulkarni
- Department of Clinical Pharmacology and Therapeutics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB20QQ, UK.
| | - Mark Glover
- Division of Therapeutics and Molecular Medicine, School of Medicine, University of Nottingham, Nottingham, NG7 2UH, UK
| | - Vikas Kapil
- William Harvey Research Institute, Centre for Cardiovascular Medicine and Devices, Queen Mary University London, London, EC1M 6BQ, UK
- Barts BP Centre of Excellence, Barts Heart Centre, London, EC1A 7BE, UK
| | - S M L Abrams
- Clinical Pharmacology and Therapeutics, Homerton Healthcare NHS Foundation Trust, London, E9 6SR, UK
| | - Sarah Partridge
- Department of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, BN1 9PH, UK
| | - Terry McCormack
- Institute of Clinical and Applied Health Research, Hull York Medical School, Hull, HU6 7RX, UK
| | - Peter Sever
- Imperial College School of Medicine, London, SW7 1LY, UK
| | - Christian Delles
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, G12 8TA, UK
| | - Ian B Wilkinson
- Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, CB2 0QQ, UK
| |
Collapse
|
8
|
Shabbir A, Chhetri I, Khambata RS, Parakaw T, Lau C, Aubdool MABN, Massimo G, Dyson N, Kapil V, Godec T, Apea V, Flint J, Orkin C, Rathod KS, Ahluwalia A. A double-blind, randomised, placebo-controlled parallel study to investigate the effect of sex and dietary nitrate on COVID-19 vaccine-induced vascular dysfunction in healthy men and women: protocol of the DiNOVasc-COVID-19 study. Trials 2023; 24:593. [PMID: 37715222 PMCID: PMC10504715 DOI: 10.1186/s13063-023-07616-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 08/30/2023] [Indexed: 09/17/2023] Open
Abstract
BACKGROUND Cardiovascular events, driven by endothelial dysfunction, are a recognised complication of COVID-19. SARS-CoV-2 infections remain a persistent concern globally, and an understanding of the mechanisms causing endothelial dysfunction, particularly the role of inflammation, nitric oxide, and whether sex differences exist in this response, is lacking. We have previously demonstrated important sex differences in the inflammatory response and its impact on endothelial function and separately that the ingestion of inorganic nitrate can protect the endothelium against this dysfunction. In this study, we will investigate whether sex or a dietary inorganic nitrate intervention modulates endothelial function and inflammatory responses after the COVID-19 vaccine. METHODS DiNOVasc-COVID-19 is a double-blind, randomised, single-centre, placebo-controlled clinical trial. A total of 98 healthy volunteers (49 males and 49 females) will be recruited. Participants will be randomised into 1 of 2 sub-studies: part A or part B. Part A will investigate the effects of sex on vascular and inflammatory responses to the COVID-19 vaccine. Part B will investigate the effects of sex and dietary inorganic nitrate on vascular and inflammatory responses to the COVID-19 vaccine. In part B, participants will be randomised to receive 3 days of either nitrate-containing beetroot juice (intervention) or nitrate-deplete beetroot juice (placebo). The primary outcome for both sub-studies is a comparison of the change in flow-mediated dilatation (FMD) from baseline after COVID-19 vaccination. The study has a power of > 80% to assess the primary endpoint. Secondary endpoints include change from baseline in inflammatory and leukocyte counts and in pulse wave analysis (PWA) and pulse wave velocity (PWV) following the COVID-19 vaccination. DISCUSSION This study aims to evaluate whether sex or dietary influences endothelial function and inflammatory responses in healthy volunteers after receiving the COVID-19 vaccine. TRIAL REGISTRATION ClinicalTrials.gov NCT04889274. Registered on 5 May 2023. The study was approved by the South Central - Oxford C Research Ethics Committee (21/SC/0154).
Collapse
Affiliation(s)
- Asad Shabbir
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
- Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Ismita Chhetri
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Rayomand S Khambata
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Tipparat Parakaw
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Clement Lau
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
- Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Muhammad A B N Aubdool
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Gianmichele Massimo
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Nicki Dyson
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Vikas Kapil
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Thomas Godec
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Vanessa Apea
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
| | - Jan Flint
- Barts Health NHS Trust, The Royal London Hospital, London, UK
| | - Chloe Orkin
- Barts Health NHS Trust, The Royal London Hospital, London, UK
| | - Krishnaraj S Rathod
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
- Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Amrita Ahluwalia
- Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK.
| |
Collapse
|
9
|
Robbins AJ, Che Bakri NA, Toke‐Bjolgerud E, Edwards A, Vikraman A, Michalsky C, Fossler M, Lemm N, Medhipour S, Budd W, Gravani A, Hurley L, Kapil V, Jackson A, Lonsdale D, Latham V, Laffan M, Chapman N, Cooper N, Szydlo R, Boyle J, Pollock KM, Owen D. The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trial. Br J Clin Pharmacol 2023; 89:1495-1501. [PMID: 36437688 PMCID: PMC10952550 DOI: 10.1111/bcp.15618] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 11/13/2022] [Accepted: 11/18/2022] [Indexed: 11/29/2022] Open
Abstract
COVID-19 causes significant thrombosis and coagulopathy, with elevated D-dimer a predictor of adverse outcome. The precise mechanism of this coagulopathy remains unclear; one hypothesis is that loss of angiotensin-converting enzyme 2 activity during viral endocytosis leads to pro-inflammatory angiotensin-II accumulation, loss of angiotensin-1-7 and subsequent vascular endothelial activation. We undertook a double-blind randomized, placebo-controlled experimental medicine study to assess the effect of TRV027, a synthetic angiotensin-1-7 analogue on D-dimer in 30 patients admitted to hospital with COVID-19. The study showed a similar rate of adverse events in TRV027 and control groups. There was a numerical decrease in D-dimer in the TRV027 group and increase in D-dimer in the placebo group; however, this did not reach statistical significance (P = .15). A Bayesian analysis demonstrated that there was a 92% probability that this change represented a true drug effect.
Collapse
Affiliation(s)
- Alexander J. Robbins
- Imperial College Research FacilityImperial College LondonLondonUK
- Imperial College Healthcare NHS TrustLondonUK
| | - Nur Amalina Che Bakri
- Imperial College Healthcare NHS TrustLondonUK
- Department of Surgery and CancerImperial College LondonLondonUK
| | | | - Aaron Edwards
- Imperial College Research FacilityImperial College LondonLondonUK
| | - Asha Vikraman
- Imperial College Research FacilityImperial College LondonLondonUK
| | | | | | - Nana‐Marie Lemm
- Imperial College Research FacilityImperial College LondonLondonUK
| | - Savviz Medhipour
- Imperial College Research FacilityImperial College LondonLondonUK
| | - William Budd
- Imperial College Research FacilityImperial College LondonLondonUK
| | | | - Lisa Hurley
- Imperial College Research FacilityImperial College LondonLondonUK
- Imperial College Healthcare NHS TrustLondonUK
| | - Vikas Kapil
- William Harvey Research Institute, Centre for Cardiovascular Medicine and Devices, Faculty of Medicine and DentistryQueen Mary University LondonLondonUK
| | - Aimee Jackson
- Cancer Research Clinical Trials UnitUniversity of BirminghamBirminghamUK
| | - Dagan Lonsdale
- Department of Clinical PharmacologySt George's University of LondonLondonUK
- Department of Critical CareSt George's University Hospitals NHS Foundation TrustLondonUK
| | | | | | | | - Nichola Cooper
- Department of Inflammation and ImmunityImperial College LondonLondonUK
| | | | - Joseph Boyle
- Imperial College Healthcare NHS TrustLondonUK
- National Heart and Lung InstituteImperial College LondonLondonUK
| | | | - David Owen
- Imperial College Research FacilityImperial College LondonLondonUK
- Department of Brain SciencesImperial College LondonLondonUK
| |
Collapse
|
10
|
Affiliation(s)
- Joshua Schier
- From the Centers for Disease Control and Prevention, Atlanta
| | - Arthur Chang
- From the Centers for Disease Control and Prevention, Atlanta
| | - Vikas Kapil
- From the Centers for Disease Control and Prevention, Atlanta
| |
Collapse
|
11
|
Khanji MY, Collett G, Godec T, Maniero C, Ng SM, Siddiqui I, Gupta J, Kapil V, Gupta A. Improved lifestyle is associated with improved depression, anxiety and well-being over time in UK healthcare professionals during the COVID-19 pandemic: insights from the CoPE-HCP cohort study. Gen Psychiatr 2023; 36:e100908. [PMID: 36751400 PMCID: PMC9895916 DOI: 10.1136/gpsych-2022-100908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 12/17/2022] [Indexed: 01/25/2023] Open
Abstract
Background One potential modifiable factor to improve the mental health of healthcare professionals (HCPs) during the pandemic is lifestyle. Aims This study aimed to assess whether an improved lifestyle during the pandemic is associated with improved mental health symptoms and mental well-being in HCPs over time. Methods This was a cohort study involving an online survey distributed at two separate time points during the pandemic (baseline (July-September 2020) and follow-up (December 2020-March 2021)) to HCPs working in primary or secondary care in the UK. Both surveys assessed for major depressive disorder (MDD) (Patient Health Questionnaire-9 (PHQ-9)), generalised anxiety disorder (GAD) (Generalised Anxiety Disorder-7 (GAD-7)), mental well-being (Short Warwick-Edinburgh Mental Well-being Score (SWEMWBS)) and self-reported lifestyle change (compared with the start of the pandemic) on multiple domains. Cumulative scores were calculated to estimate overall lifestyle change compared with that before the pandemic (at both baseline and follow-up). At each time point, separate logistic regression models were constructed to relate the lifestyle change score with the presence of MDD, GAD and low mental well-being. Linear regression models were also developed relating the change in lifestyle scores from baseline to follow-up to changes in PHQ-9, GAD-7 and SWEMWBS scores. Results 613 HCPs completed both baseline assessment and follow-up assessment. Consistent significant cross-sectional associations between increased lifestyle change scores and a reduced risk of MDD, GAD and low mental well-being were observed at both baseline and follow-up. Over the study period, a whole unit increase in the change in novel scores (ie, improved overall lifestyle) over 4 months was inversely associated with changes in PHQ-9 (adjusted coefficient: -0.51, 95% confidence interval (CI): -0.73 to -0.30, p<0.001) and GAD-7 scores (adjusted coefficient: -0.32, 95% CI: -0.53 to -0.10, p=0.004) and positively associated with the change in SWEMWBS scores (adjusted coefficient: 0.37, 95% CI: 0.18 to 0.55, p<0.001). Conclusions Improved lifestyle over time is associated with improved mental health and mental well-being in HCPs during the pandemic. Improving lifestyle could be a recommended intervention for HCPs to help mitigate the mental health impact during the current and future pandemics. Trial registration number NCT04433260.
Collapse
Affiliation(s)
- Mohammed Y Khanji
- William Harvey Research Institute, Queen Mary University of London, London, UK,Department of Cardiology, Barts Heart Centre, Saint Bartholomew's Hospital, Barts Health NHS Trust, London, UK,Newham University Hospital, Barts Health NHS Trust, London, UK
| | - George Collett
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Thomas Godec
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Carmela Maniero
- William Harvey Research Institute, Queen Mary University of London, London, UK,Department of Cardiology, Barts Heart Centre, Saint Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Sher May Ng
- Department of Cardiology, Barts Heart Centre, Saint Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Imrana Siddiqui
- Wellbeing Hub, Newham Training Hub, London, UK,NHS North East London CCG, London, UK
| | - Jaya Gupta
- Child and Adolescent Mental Health Service, South West London and St George's Mental Health NHS Trust, London, UK
| | - Vikas Kapil
- William Harvey Research Institute, Queen Mary University of London, London, UK,Department of Cardiology, Barts Heart Centre, Saint Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Ajay Gupta
- William Harvey Research Institute, Queen Mary University of London, London, UK,Department of Cardiology, Barts Heart Centre, Saint Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| |
Collapse
|
12
|
Rathod KS, Kapil V, Velmurugan S, Khambata RS, Siddique U, Khan S, Van Eijl S, Gee LC, Bansal J, Pitrola K, Shaw C, D'Acquisto F, Colas RA, Marelli-Berg F, Dalli J, Ahluwalia A. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J Clin Invest 2023; 133:168068. [PMID: 36647837 PMCID: PMC9843040 DOI: 10.1172/jci168068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
13
|
Maniero C, Lopuszko A, Papalois KB, Gupta A, Kapil V, Khanji MY. Non-pharmacological factors for hypertension management: a systematic review of international guidelines. Eur J Prev Cardiol 2023; 30:17-33. [PMID: 35947982 DOI: 10.1093/eurjpc/zwac163] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 07/29/2022] [Accepted: 08/01/2022] [Indexed: 01/19/2023]
Abstract
Lifestyle modifications are one of the cornerstones of hypertension prevention and treatment. We aimed to systematically review hypertension guidelines on their recommendations on non-pharmacological factors including lifestyle interventions, to highlight strength of evidence, similarities, and differences. This systematic review was registered with the international Prospective Register of Systematic Reviews (CRD42021288815). Publications in MEDLINE and EMBASE databases over 10 years since January 2010 to June 2020 were identified. We also included the search from websites of organizations responsible for guidelines development. Two reviewers screened the titles and abstracts to identify relevant guidelines. Two reviewers independently assessed rigour of guideline development using the AGREE II instrument, and one reviewer extracted recommendations. Of the identified guidelines, 10 showed good rigour of development (AGREE II ≥ 60%) and were included in the systematic review. The guidelines were consistent in most recommendations (reduced salt intake, weight, dietary patterns, increased physical activity and smoking cessation, and limiting alcohol intake). Some areas of disagreement were identified, regarding recommendations on novel psychological and environmental factors such as stress or air pollution, alcohol intake thresholds, meat, coffee and tea consumption and refined sugars. Current guidelines agree on the importance of lifestyle in the treatment and prevention of hypertension. Consensus on smoking cessation, limited salt intake, increased physical activity support their integration in management of hypertensive patients and in public health measurements in general population as preventative measurements. Further research into the role of environmental and psychological factors may help clarify future recommendations.
Collapse
Affiliation(s)
- Carmela Maniero
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London EC1A 7BE, UK.,NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Aleksandra Lopuszko
- NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Kyriaki-Barbara Papalois
- NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Ajay Gupta
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London EC1A 7BE, UK.,NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Vikas Kapil
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London EC1A 7BE, UK.,NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Mohammed Y Khanji
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London EC1A 7BE, UK.,NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.,Newham University Hospital, Barts Health NHS Trust, London E13 8SL, UK
| |
Collapse
|
14
|
Siddiqui I, Gupta J, Collett G, McIntosh I, Komodromos C, Godec T, Ng S, Maniero C, Antoniou S, Khan R, Kapil V, Khanji MY, Gupta AK. Perceived workplace support and mental health, well-being and burnout among health care professionals during the COVID-19 pandemic: a cohort analysis. CMAJ Open 2023; 11:E191-E200. [PMID: 36854456 PMCID: PMC9981163 DOI: 10.9778/cmajo.20220191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/02/2023] Open
Abstract
BACKGROUND Little is known about the relationship between workplace support and mental health and burnout among health care professionals (HCPs) during the COVID-19 pandemic. In this cohort study, we sought to evaluate the association between perceived level of (and changes to) workplace support and mental health and burnout among HCPs, and to identify what constitutes perceived effective workplace support. METHODS Online surveys at baseline (July-September 2020) and follow-up 4 months later assessed the presence of generalized anxiety disorder (using the 7-item Generalized Anxiety Disorder scale [GAD-7]), clinical insomnia, major depressive disorder (using the 9-item Patient Health Questionnaire), burnout (emotional exhaustion and depersonalization) and mental well-being (using the Short Warwick-Edinburgh Mental Wellbeing Score). Both surveys assessed self-reported level of workplace support (single-item Likert scale). For baseline and follow-up, independently, we developed separate logistic regression models to evaluate the association of the level of workplace support (tricohotomized as unsupported, neither supported nor unsupported and supported) with mental health and burnout. We also developed linear regression models to evaluate the association between the change in perceived level of workplace support and the change in mental health scores from baseline and follow-up. We used thematic analyses on free-text entries of the baseline survey to evaluate what constitutes effective support. RESULTS At baseline (n = 1422) and follow-up (n = 681), HCPs who felt supported had reduced risk of anxiety, depression, clinical insomnia, emotional exhaustion and depersonalization, compared with those who felt unsupported. Among those who responded to both surveys (n = 681), improved perceived level of workplace support over time was associated with significantly improved scores on measures of anxiety (adjusted β -0.13, 95% confidence interval [CI] -0.25 to -0.01), depression (adjusted β -0.17, 95% CI -0.29 to -0.04) and mental well-being (adjusted β 0.19, 95% CI 0.10 to 0.29), independent of baseline level of support. We identified 5 themes constituting effective workplace support, namely concern or understanding for welfare, information, tangible qualities of the workplace, leadership and peer support. INTERPRETATION We found a significant association between perceived level of (and changes in) workplace support and mental health and burnout of HCPs, and identified potential themes that constitute perceived workplace support. Collectively, these findings can inform changes in guidance and national policies to improve mental health and burnout among HCPs. Trial registration: ClinicalTrials.gov, no. NCT04433260.
Collapse
Affiliation(s)
- Imrana Siddiqui
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Jaya Gupta
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - George Collett
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Iris McIntosh
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Christina Komodromos
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Thomas Godec
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Sher Ng
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Carmela Maniero
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Sotiris Antoniou
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Rehan Khan
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Vikas Kapil
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Mohammed Y Khanji
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| | - Ajay K Gupta
- Wellbeing Hub (Siddiqui), Newham Training Hub; NHS NorthEast London CCG (Siddiqui); Woodgrange Medical Practice (Siddiqui); South West London and St George's Mental Health NHS Trust (J. Gupta); William Harvey Research Institute (Collett, Godec, Maniero, Kapil, Khanji, A.K. Gupta), Queen Mary University of London; Camden & Islington Foundation Trust (McIntosh); Barnet, Enfield and Haringey Mental Health NHS Trust (Komodromos); Barts Heart Centre (Ng, Maniero, Antoniou, Kapil, Khanji, A.K. Gupta), St. Bartholomew's Hospital and The Royal London Hospital (Maniero, Khan, Kapil, A.K. Gupta), and Newham University Hospital (Khanji), Barts Health NHS Trust; National Heart and Lung Institute (A.K. Gupta), Imperial College London, London, UK
| |
Collapse
|
15
|
Kapil V, Collett G, Godec T, Gupta J, Maniero C, Ng SM, McIntosh I, Kumar A, Nair S, Kotecha A, Janmohamed A, Antoniou S, Khan R, Khanji MY, Siddiqui I, Gupta A. Longitudinal comparisons of mental health, burnout and well-being in patient-facing, non-patient-facing healthcare professionals and non-healthcare professionals during the COVID-19 pandemic: findings from the CoPE-HCP study. BJPsych Open 2022; 8:e173. [PMID: 36164721 PMCID: PMC9530379 DOI: 10.1192/bjo.2022.579] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND The COVID-19 pandemic may disproportionately affect the mental health of healthcare professionals (HCPs), especially patient-facing HCPs. AIMS To longitudinally examine mental health in HCPs versus non-HCPs, and patient-facing HCPs versus non-patient-facing HCPs. METHOD Online surveys were distributed to a cohort at three phases (baseline, July to September 2020; phase 2, 6 weeks post-baseline; phase 3, 4 months post-baseline). Each survey contained validated assessments for depression, anxiety, insomnia, burnout and well-being. For each outcome, we conducted mixed-effects logistic regression models (adjusted for a priori confounders) comparing the risk in different groups at each phase. RESULTS A total of 1574 HCPs and 147 non-HCPs completed the baseline survey. Although there were generally higher rates of various probable mental health issues among HCPs versus non-HCPs at each phase, there was no significant difference, except that HCPs had 2.5-fold increased risk of burnout at phase 2 (emotional exhaustion: odds ratio 2.50, 95% CI 1.15-5.46, P = 0.021), which increased at phase 3 (emotional exhaustion: odds ratio 3.32, 95% CI 1.40-7.87, P = 0.006; depersonalisation: odds ratio 3.29, 95% CI 1.12-9.71, P = 0.031). At baseline, patient-facing HCPs (versus non-patient-facing HCPs) had a five-fold increased risk of depersonalisation (odds ratio 5.02, 95% CI 1.65-15.26, P = 0.004), with no significant difference in the risk for other outcomes. The difference in depersonalisation reduced over time, but patient-facing HCPs still had a 2.7-fold increased risk of emotional exhaustion (odds ratio 2.74, 95% CI 1.28-5.85, P = 0.009) by phase 3. CONCLUSIONS The COVID-19 pandemic had a huge impact on the mental health and well-being of both HCPs and non-HCPs, but there is disproportionately higher burnout among HCPs, particularly patient-facing HCPs.
Collapse
Affiliation(s)
- Vikas Kapil
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, UK; William Harvey Research Institute, Queen Mary University of London, UK; and Department of Clinical Pharmacology, The Royal London Hospital, Barts Health NHS Trust, UK
| | - George Collett
- William Harvey Research Institute, Queen Mary University of London, UK
| | - Thomas Godec
- William Harvey Research Institute, Queen Mary University of London, UK
| | - Jaya Gupta
- Child and Adolescent Mental Health Service, South West London and St George's Mental Health NHS Trust, UK
| | - Carmela Maniero
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, UK; and William Harvey Research Institute, Queen Mary University of London, UK
| | - Sher M Ng
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, UK
| | - Iris McIntosh
- Islington Learning Disability Partnership, Camden & Islington Foundation Trust, UK
| | - Abhishek Kumar
- Department of Cardiology, Wrightington, Wigan and Leigh NHS Foundation Trust, UK
| | - Satheesh Nair
- Department of Cardiology, Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, UK
| | - Ashish Kotecha
- Department of Cardiology, Royal Devon and Exeter Hospital, UK
| | - Azara Janmohamed
- Department of Clinical Pharmacology, St George's University Hospitals NHS Foundation Trust, UK
| | - Sotiris Antoniou
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, UK; and Cardiovascular Health, UCLPartners, UK
| | - Rehan Khan
- Department of Obstetrics and Gynaecology, The Royal London Hospital, Barts Health NHS Trust, UK
| | - Mohammed Y Khanji
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, UK; William Harvey Research Institute, Queen Mary University of London, UK; Cardiovascular Health, UCLPartners, UK; and Department of Cardiology, Newham University Hospital, Barts Health NHS Trust, UK
| | - Imrana Siddiqui
- Wellbeing Hub, Newham Training Hub, UK; NHS North East London Integrated Care Board (ICB), UK; and Woodgrange Medical Practice, UK
| | - Ajay Gupta
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, UK; William Harvey Research Institute, Queen Mary University of London, UK; and Department of Clinical Pharmacology, The Royal London Hospital, Barts Health NHS Trust, UK
| |
Collapse
|
16
|
Doykov I, Baldwin T, Spiewak J, Gilmour KC, Gibbons JM, Pade C, Reynolds CJ, Áine McKnight, Noursadeghi M, Maini MK, Manisty C, Treibel T, Captur G, Fontana M, Boyton RJ, Altmann DM, Brooks T, Semper A, Moon JC, Kevin Mills, Heywood WE, Abiodun A, Alfarih M, Alldis Z, Altmann DM, Amin OE, Andiapen M, Artico J, Augusto JB, Baca GL, Bailey SN, Bhuva AN, Boulter A, Bowles R, Boyton RJ, Bracken OV, O’Brien B, Brooks T, Bullock N, Butler DK, Captur G, Carr O, Champion N, Chan C, Chandran A, Coleman T, Couto de Sousa J, Couto-Parada X, Cross E, Cutino-Moguel T, D’Arcangelo S, Davies RH, Douglas B, Di Genova C, Dieobi-Anene K, Diniz MO, Ellis A, Feehan K, Finlay M, Fontana M, Forooghi N, Francis S, Gibbons JM, Gillespie D, Gilroy D, Hamblin M, Harker G, Hemingway G, Hewson J, Heywood W, Hickling LM, Hicks B, Hingorani AD, Howes L, Itua I, Jardim V, Lee WYJ, Jensen M, Jones J, Jones M, Joy G, Kapil V, Kelly C, Kurdi H, Lambourne J, Lin KM, Liu S, Lloyd A, Louth S, Maini MK, Mandadapu V, Manisty C, McKnight Á, Menacho K, Mfuko C, Mills K, Millward S, Mitchelmore O, Moon C, Moon J, Sandoval DM, Murray SM, Noursadeghi M, Otter A, Pade C, Palma S, Parker R, Patel K, Pawarova M, Petersen SE, Piniera B, Pieper FP, Rannigan L, Rapala A, Reynolds CJ, Richards A, Robathan M, Rosenheim J, Rowe C, Royds M, West JS, Sambile G, Schmidt NM, Selman H, Semper A, Seraphim A, Simion M, Smit A, Sugimoto M, Swadling L, Taylor S, Temperton N, Thomas S, Thornton GD, Treibel TA, Tucker A, Varghese A, Veerapen J, Vijayakumar M, Warner T, Welch S, White H, Wodehouse T, Wynne L, Zahedi D. Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response. Cell Rep Methods 2022; 2:100279. [PMID: 35975199 PMCID: PMC9372021 DOI: 10.1016/j.crmeth.2022.100279] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 06/24/2022] [Accepted: 08/05/2022] [Indexed: 02/09/2023]
Abstract
Determining the protection an individual has to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VoCs) is crucial for future immune surveillance, vaccine development, and understanding of the changing immune response. We devised an informative assay to current ELISA-based serology using multiplexed, baited, targeted proteomics for direct detection of multiple proteins in the SARS-CoV-2 anti-spike antibody immunocomplex. Serum from individuals collected after infection or first- and second-dose vaccination demonstrates this approach and shows concordance with existing serology and neutralization. Our assays show altered responses of both immunoglobulins and complement to the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.1) VoCs and a reduced response to Omicron (B1.1.1529). We were able to identify individuals who had prior infection, and observed that C1q is closely associated with IgG1 (r > 0.82) and may better reflect neutralization to VoCs. Analyzing additional immunoproteins beyond immunoglobulin (Ig) G, provides important information about our understanding of the response to infection and vaccination.
Collapse
Affiliation(s)
- Ivan Doykov
- Translational Mass Spectrometry Research Group, Genetics & Genomic Medicine Department, UCL Institute of Child Health, London, UK.,Great Ormond Street Biomedical Research Centre, UCL Institute of Child Health London
| | - Tomas Baldwin
- Translational Mass Spectrometry Research Group, Genetics & Genomic Medicine Department, UCL Institute of Child Health, London, UK
| | - Justyna Spiewak
- Translational Mass Spectrometry Research Group, Genetics & Genomic Medicine Department, UCL Institute of Child Health, London, UK
| | - Kimberly C Gilmour
- Great Ormond Street Children's Hospital NHS Foundation Trust, Great Ormond Street, London WC1N 3JH, UK
| | - Joseph M Gibbons
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Corinna Pade
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | | | - Áine McKnight
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Mahdad Noursadeghi
- Division of Infection and Immunity, University College London, London, UK
| | - Mala K Maini
- Division of Infection and Immunity, University College London, London, UK
| | - Charlotte Manisty
- St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.,Institute of Cardiovascular Science, University College London, London, UK
| | - Thomas Treibel
- St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.,Institute of Cardiovascular Science, University College London, London, UK
| | - Gabriella Captur
- Institute of Cardiovascular Science, University College London, London, UK.,Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK
| | - Marianna Fontana
- Institute of Cardiovascular Science, University College London, London, UK.,Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK
| | - Rosemary J Boyton
- Department of Infectious Disease, Imperial College London, London, UK.,Lung Division, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - Daniel M Altmann
- Department of Immunology and Inflammation, Imperial College London, London, UK
| | - Tim Brooks
- UK Health Security Agency, Porton Down, UK
| | | | | | - James C Moon
- St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.,Institute of Cardiovascular Science, University College London, London, UK
| | - Kevin Mills
- Translational Mass Spectrometry Research Group, Genetics & Genomic Medicine Department, UCL Institute of Child Health, London, UK.,Great Ormond Street Biomedical Research Centre, UCL Institute of Child Health London
| | - Wendy E Heywood
- Translational Mass Spectrometry Research Group, Genetics & Genomic Medicine Department, UCL Institute of Child Health, London, UK.,Great Ormond Street Biomedical Research Centre, UCL Institute of Child Health London
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Muñoz Sandoval D, Pieper FP, Butler DK, Liu S, Joy G, Forooghi N, Treibel TA, Manisty C, Moon JC, Semper A, Brooks T, McKnight Á, Altmann DM, Boyton RJ, Abbass H, Abiodun A, Alfarih M, Alldis Z, Altmann DM, Amin OE, Andiapen M, Artico J, Augusto JB, Baca GL, Bailey SNL, Bhuva AN, Boulter A, Bowles R, Boyton RJ, Bracken OV, O'Brien B, Brooks T, Bullock N, Butler DK, Captur G, Carr O, Champion N, Chan C, Chandran A, Coleman T, Couto de Sousa J, Couto-Parada X, Cross E, Cutino-Moguel T, D'Arcangelo S, Davies RH, Douglas B, Di Genova C, Dieobi-Anene K, Diniz MO, Ellis A, Feehan K, Finlay M, Fontana M, Forooghi N, Francis S, Gibbons JM, Gillespie D, Gilroy D, Hamblin M, Harker G, Hemingway G, Hewson J, Heywood W, Hickling LM, Hicks B, Hingorani AD, Howes L, Itua I, Jardim V, Lee WYJ, Jensen M, Jones J, Jones M, Joy G, Kapil V, Kelly C, Kurdi H, Lambourne J, Lin KM, Liu S, Lloyd A, Louth S, Maini MK, Mandadapu V, Manisty C, McKnight Á, Menacho K, Mfuko C, Mills K, Millward S, Mitchelmore O, Moon C, Moon J, Muñoz Sandoval D, Murray SM, Noursadeghi M, Otter A, Pade C, Palma S, Parker R, Patel K, Pawarova M, Petersen SE, Piniera B, Pieper FP, Rannigan L, Rapala A, Reynolds CJ, Richards A, Robathan M, Rosenheim J, Rowe C, Royds M, Sackville West J, Sambile G, Schmidt NM, Selman H, Semper A, Seraphim A, Simion M, Smit A, Sugimoto M, Swadling L, Taylor S, Temperton N, Thomas S, Thornton GD, Treibel TA, Tucker A, Varghese A, Veerapen J, Vijayakumar M, Warner T, Welch S, White H, Wodehouse T, Wynne L, Zahedi D, Chain B, Moon JC. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 2022; 377:eabq1841. [PMID: 35699621 PMCID: PMC9210451 DOI: 10.1126/science.abq1841] [Citation(s) in RCA: 187] [Impact Index Per Article: 93.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Accepted: 06/06/2022] [Indexed: 12/15/2022]
Abstract
The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple BioNTech BNT162b2 messenger RNA-vaccinated health care workers (HCWs) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple-vaccinated individuals, but the magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCWs who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.
Collapse
Affiliation(s)
| | - Corinna Pade
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Joseph M Gibbons
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | | | - Kai-Min Lin
- Department of Infectious Disease, Imperial College London, London, UK
| | | | | | - David K Butler
- Department of Infectious Disease, Imperial College London, London, UK
| | - Siyi Liu
- Department of Infectious Disease, Imperial College London, London, UK
| | - George Joy
- St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Nasim Forooghi
- St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Thomas A Treibel
- St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.,Institute of Cardiovascular Science, University College London, London, UK
| | - Charlotte Manisty
- St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.,Institute of Cardiovascular Science, University College London, London, UK
| | - James C Moon
- St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.,Institute of Cardiovascular Science, University College London, London, UK
| | | | | | | | - Tim Brooks
- UK Health Security Agency, Porton Down, UK
| | - Áine McKnight
- Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Daniel M Altmann
- Department of Immunology and Inflammation, Imperial College London, London, UK
| | - Rosemary J Boyton
- Department of Infectious Disease, Imperial College London, London, UK.,Lung Division, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Ng SM, Pan J, Mouyis K, Kondapally Seshasai SR, Kapil V, Rice KM, Gupta AK. Quantifying the Excess Risk of Adverse COVID-19 Outcomes in Unvaccinated Individuals With Diabetes Mellitus, Hypertension, Ischaemic Heart Disease or Myocardial Injury: A Meta-Analysis. Front Cardiovasc Med 2022; 9:871151. [PMID: 35557537 PMCID: PMC9090337 DOI: 10.3389/fcvm.2022.871151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 04/01/2022] [Indexed: 12/03/2022] Open
Abstract
Background More than 80% of individuals in low and middle-income countries (LMICs) are unvaccinated against coronavirus disease 2019 (COVID-19). In contrast, the greatest burden of cardiovascular disease is seen in LMIC populations. Hypertension (HTN), diabetes mellitus (DM), ischaemic heart disease (IHD) and myocardial injury have been variably associated with adverse COVID-19 outcomes. A systematic comparison of their impact on specific COVID-19 outcomes is lacking. We quantified the impact of DM, HTN, IHD and myocardial injury on six adverse COVID-19 outcomes: death, acute respiratory distress syndrome (ARDS), invasive mechanical ventilation (IMV), admission to intensive care (ITUadm), acute kidney injury (AKI) and severe COVID-19 disease (SCov), in an unvaccinated population. Methodology We included studies published between 1st December 2019 and 16th July 2020 with extractable data on patients ≥18 years of age with suspected or confirmed SARS-CoV-2 infection. Odds ratios (OR) for the association between DM, HTN, IHD and myocardial injury with each of six COVID-19 outcomes were measured. Results We included 110 studies comprising 48,809 COVID-19 patients. Myocardial injury had the strongest association for all six adverse COVID-19 outcomes [death: OR 8.85 95% CI (8.08–9.68), ARDS: 5.70 (4.48–7.24), IMV: 3.42 (2.92–4.01), ITUadm: 4.85 (3.94–6.05), AKI: 10.49 (6.55–16.78), SCov: 5.10 (4.26–6.05)]. HTN and DM were also significantly associated with death, ARDS, ITUadm, AKI and SCov. There was substantial heterogeneity in the results, partly explained by differences in age, gender, geographical region and recruitment period. Conclusion COVID-19 patients with myocardial injury are at substantially greater risk of death, severe disease and other adverse outcomes. Weaker, yet significant associations are present in patients with HTN, DM and IHD. Quantifying these associations is important for risk stratification, resource allocation and urgency in vaccinating these populations. Systematic Review Registration https://www.crd.york.ac.uk/prospero/, registration no: CRD42020201435 and CRD42020201443.
Collapse
Affiliation(s)
- Sher May Ng
- St. Bartholomew's Hospital, London, United Kingdom
| | - Jiliu Pan
- Royal Brompton and Harefield Hospitals, London, United Kingdom
| | - Kyriacos Mouyis
- Royal Free London NHS Foundation Trust, London, United Kingdom
| | - Sreenivasa Rao Kondapally Seshasai
- Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's University of London, St. George's University Hospitals NHS Foundation Trust, London, United Kingdom
| | - Vikas Kapil
- William Harvey Research Institute, Queen Mary University London, London, United Kingdom
| | - Kenneth M. Rice
- Department of Biostatistics, University of Washington, Seattle, WA, United States
| | - Ajay K. Gupta
- William Harvey Research Institute, Queen Mary University London, London, United Kingdom
- *Correspondence: Ajay K. Gupta
| |
Collapse
|
19
|
Lau C, Shabbir A, Rathod KS, Chhetri I, Ono M, Hamers AJP, Amarin JJ, Ibrahim A, Nuredini G, Godec T, Kapil V, Ahluwalia A. Inorganic nitrate attenuates endothelial dysfunction consequent to systemic inflammation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Chronic cardiovascular diseases are characterised by low-grade systemic inflammation and attenuated nitric oxide (NO) bioavailability resulting in endothelial dysfunction. Inorganic nitrate augments NO bioavailability and improves markers of vascular dysfunction in patients with cardiovascular risk factors. However, the exact mechanism of this effect is uncertain.
Purpose
To determine whether inorganic nitrate supplementation alters systemic inflammation-induced endothelial dysfunction.
Methods
62 healthy male volunteers were randomised 1:1 to receive ∼8–10 mmol of dietary inorganic nitrate in beetroot juice or nitrate-free beetroot juice (placebo) once daily for 6 days. Measures of brachial artery flow-mediated dilatation (FMD), brachial blood pressure (BP), pulse wave analysis and carotid-femoral pulse wave velocity (PWV) by Vicorder were taken prior to and at 8 hours after a typhoid vaccine (to induce mild systemic inflammation). Plasma, urine and saliva samples were also collected. Clinicaltrials.gov: NCT02715635.
Results
Baseline characteristics were similar between the two groups. Inorganic nitrate significantly elevated plasma nitrite (placebo = Δ0.02±0.5 μM, inorganic nitrate = Δ0.63±1.2 μM; p=0.01) and nitrate levels (p<0.0001) compared to placebo. There were significant increases in urine nitrite (p<0.0001) and nitrate (p<0.0001) in addition to salivary nitrite (p<0.0001) and nitrate (p<0.0001) compared to placebo. After 8 hours, typhoid vaccine induced an increase in circulating white cells (placebo = Δ3.34±3.37x109/L, inorganic nitrate = Δ2.9±2.78x109/L; p=0.58) that was similar in in both arms. However, there was a significant reduction in the FMD response in the placebo group at 8-hours post vaccine; an effect that was absent in volunteers treated with inorganic nitrate (placebo = Δ−1.33±1.53%, inorganic nitrate = Δ−0.07±1.84%, p=0.005). Importantly, there were no statistically significant differences in baseline vessel diameter (p=0.78), time to peak diameter in response to flow (p=0.87) and peak shear rate (p=0.57) between the groups. When comparing change from baseline to 8 hours after the vaccine, there were no significant differences in brachial systolic BP (p=0.12), central systolic BP (p=0.12) and PWV (p=0.60) between groups, but a significant reduction in brachial diastolic BP in the inorganic nitrate group (p=0.048).
Conclusions
Inflammation-induced endothelial dysfunction was prevented in those receiving dietary inorganic nitrate suggesting that elevating circulating nitrite and delivering NO to the blood vessel wall, through dietary approaches may offer potential therapeutic benefit in those cardiovascular diseases which typically exhibit low grade inflammation and deficiencies in bioavailable NO.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): British Heart Foundation
Collapse
Affiliation(s)
- C Lau
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - A Shabbir
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - K S Rathod
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - I Chhetri
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - M Ono
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - A J P Hamers
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - J J Amarin
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - A Ibrahim
- University of Southampton, Southampton, United Kingdom
| | - G Nuredini
- Barts Health NHS Trust, London, United Kingdom
| | - T Godec
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - V Kapil
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | - A Ahluwalia
- William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| |
Collapse
|
20
|
Primus C, Masucci M, Whitear C, Montalvo Moreira SA, Ajit Kumar N, Chhetri I, Rathod KS, Khambata R, Kapil V, Ahluwalia A. A pro-resolving phenotype underpins the anti-inflammatory effects of inorganic nitrate. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Increasing evidence highlights the critical role of chronic inflammation in cardiovascular disease (CVD). Targeting inflammatory pathways in patients with CVD has been associated with improved CV function in pre-clinical (Gee, 2017), early clinical (Yndestad, 2006; Velmurugan 2013; Jones, 2016) and large phase III studies (Ridker, 2017).
The resolution of inflammation is an active process and its failure has also been proposed to contribute to CVD progression. At least one mechanism thought to underlie this failure is dysfunction of the canonical pathway for anti-inflammatory nitric oxide (NO) production. Restoring NO through provision of inorganic nitrate (NO3-) and subsequent bioactivation via the non-canonical pathway may offer therapeutic benefit.
Aim
To test whether dietary NO3–derived NO accelerates resolution of inflammation.
Methods
Randomised, double-blind, placebo-controlled, parallel limb study of 8–10mmol dietary NO3- supplementation versus NO3–deplete placebo beetroot juice in 36 healthy male volunteers (NCT03183830). Using a cantharadin-induced skin blister model (Day, 2001), acute (24h) and chronic (72h)-phase blisters were harvested pre- and post-treatment. Blister exudate was analysed for leucocyte activation state (CD11b, CD62L, CD162) by flow cytometry and cytokine/chemokine composition by ELISA. Ozone chemiluminescence established NO3-/NO2- levels in key biological matrices: plasma, urine and saliva.
Results
9.3mmol inorganic NO3- led to a significant rise (versus placebo, p<0.001) of NO3-/NO2- in plasma, saliva and urine NO2- (p<0.02). No differences were seen in blister volumes, cell counts or markers of systemic inflammation. Whilst no differences were seen in the proportions of cellular infiltrate in 24h blisters, there were significant reductions of neutrophil (p=0.017) and intermediate monocyte proportions (p=0.001) and cellular adhesion molecules across inflammatory, intermediate and resolving monocytes at 72h (Figure 1). Generally, no differences in blister cytokine/chemokine profile was evident except for borderline significant suppression of TNFα at 24hrs with dietary NO3- treatment (P=0.057).
Conclusion
Whilst dietary inorganic NO3- does not impair the essential host defence response it does accelerate resolution: enhanced pro- to anti-inflammatory monocyte subtype switching and curtailed neutrophil recruitment, likely via attenuated TNFα production. These actions offer a novel, easy to administer, approach to influence inflammatory responses without impairing host defence.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Derek Willoughby Trust and British Heart Foundation
Collapse
Affiliation(s)
- C Primus
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - M Masucci
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - C Whitear
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - S A Montalvo Moreira
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - N Ajit Kumar
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - I Chhetri
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - K S Rathod
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - R Khambata
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - V Kapil
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| | - A Ahluwalia
- Queen Mary University of London, William Harvey Research Institute, London, United Kingdom
| |
Collapse
|
21
|
Shabbir A, Lau C, Rathod KS, Chhetri I, Haque A, Godec T, Khambata RS, Kapil V, Ahluwalia A. Inorganic nitrate attenuates the systemic inflammatory response in typhoid vaccine-induced endothelial dysfunction in healthy volunteers. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Inflammatory responses underlie the development of endothelial dysfunction in CVD, however, therapeutics that might target this pathway have not been forthcoming. A key pathogenic mechanism mediating endothelial dysfunction is a reduction in bioavailable (eNOS-derived) nitric oxide (NO). Activation of the non-canonical pathway for in-vivo NO generation might offer an approach to improve NO levels and recover vascular function in pre-clinical models of CVD. Whether this might occur in humans is unknown.
Purpose
We hypothesize that consumption of inorganic nitrate will lead to increases in bioavailable NO and thus attenuate the inflammatory pathways leading to typhoid vaccine-induced endothelial dysfunction in healthy volunteers.
Methods
Healthy male volunteers were recruited (n=78) and randomized to receive either beetroot juice containing 8–10mmol nitrate or placebo (nitrate-deplete) juice once daily for 6 days. Participants underwent serial measurements of BP, FMD and GTN-induced brachial artery dilatation, and haematology and biochemistry, before and after typhoid vaccination. Blood, urine and saliva nitrite and nitrate were quantified using ozone chemiluminescence, and leukocyte flow cytometry analysis was conducted.
Results
8-hours post-vaccine endothelial function was depressed in placebo-treated volunteers, however this was prevented in nitrate-treated volunteers. This dysfunction was due to impaired endothelial function since responses to GTN were unaffected either by vaccination or dietary intervention (p=0.981). Dietary nitrate resulted in an increase in plasma (p<0.0001), urine (p=0.0006) and saliva (p<0.0001) nitrate, and urine (p=0.0354) and saliva (p<0.0001) nitrite levels. There was a reduction in the proportions of CD14++/CD16+intermediate monocytes in nitrate-treated participants after vaccine (p=0.016, change from baseline between groups). In the nitrate-treated group, less CD14++/CD16+ intermediate monocyte CD62L expression was identified post-vaccine (p=0.0122), compared to placebo, with no difference in soluble plasma CD62L between groups (p=0.875). CD11b median fluorescence intensity was increased in CD3+/CD4+ T-lymphocytes in nitrate-treated volunteers (p=0.0095).
Conclusions
Dietary nitrate reduced BP, as previously shown, indicating efficacy of the intervention. Importantly, we also now show for the first time that inorganic nitrate suppresses the systemic inflammatory response, specifically by reducing the numbers and activation state of CD14++/CD16+ intermediate monocytes. Furthermore, an increased expression of CD3+/CD4+ T-cell CD11b and preserved FMD in healthy volunteers treated with nitrate, suggests an anti-inflammatory phenotype, induced by the intervention, leading to improved endothelial function. Inorganic dietary nitrate modulates endothelial function through the attenuation of inflammatory responses and may be of potential therapeutic benefit in patients with established CAD.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Shabbir
- St Bartholomews and Queen Mary University, London, United Kingdom
| | - C Lau
- St Bartholomews and Queen Mary University, London, United Kingdom
| | - K S Rathod
- St Bartholomews and Queen Mary University, London, United Kingdom
| | - I Chhetri
- St Bartholomews and Queen Mary University, London, United Kingdom
| | - A Haque
- St Bartholomews and Queen Mary University, London, United Kingdom
| | - T Godec
- St Bartholomews and Queen Mary University, London, United Kingdom
| | - R S Khambata
- St Bartholomews and Queen Mary University, London, United Kingdom
| | - V Kapil
- St Bartholomews and Queen Mary University, London, United Kingdom
| | - A Ahluwalia
- St Bartholomews and Queen Mary University, London, United Kingdom
| |
Collapse
|
22
|
Gee LC, Massimo G, Lau C, Primus C, Fernandes D, Chen J, Rathod KS, Hamers AJP, Filomena F, Nuredini G, Ibrahim AS, Khambata RS, Gupta AK, Moon JC, Kapil V, Ahluwalia A. Inorganic nitrate attenuates cardiac dysfunction: role for xanthine oxidoreductase and nitric oxide. Br J Pharmacol 2021; 179:4757-4777. [PMID: 34309015 DOI: 10.1111/bph.15636] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 07/01/2021] [Accepted: 07/03/2021] [Indexed: 11/28/2022] Open
Abstract
Nitric oxide (NO) is a vasodilator and independent modulator of cardiac remodelling. Commonly, in cardiac disease (e.g. heart failure) endothelial dysfunction (synonymous with NO-deficiency) has been implicated in increased blood pressure (BP), cardiac hypertrophy and fibrosis. Currently no effective therapies replacing NO have succeeded in the clinic. Inorganic nitrate (NO3 - ), through chemical reduction to nitrite and then NO, exerts potent BP-lowering but whether it might be useful in treating undesirable cardiac remodelling is unknown. In a nested age- and sex-matched case-control study of hypertensive patients +/- left ventricular hypertrophy (NCT03088514) we show that lower plasma nitrite concentration and vascular dysfunction accompany cardiac hypertrophy and fibrosis in patients. In mouse models of cardiac remodelling, we also show that restoration of circulating nitrite levels using dietary nitrate improves endothelial dysfunction through targeting of xanthine oxidoreductase (XOR)-driven H2 O2 and superoxide, and reduces cardiac fibrosis through NO-mediated block of SMAD-phosphorylation leading to improvements in cardiac structure and function. We show that via these mechanisms dietary nitrate offers easily translatable therapeutic options for treatment of cardiac dysfunction.
Collapse
Affiliation(s)
- Lorna C Gee
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Gianmichele Massimo
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Clement Lau
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Christopher Primus
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Daniel Fernandes
- Departamento de Farmacologia, Federal University of Santa Catarina, Florianópolis, Santa Catarina,, Brazil
| | - Jianmin Chen
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Krishnaraj S Rathod
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Alexander Jozua Pedro Hamers
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Federica Filomena
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Gani Nuredini
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Abdiwahab Shidane Ibrahim
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Rayomand S Khambata
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Ajay K Gupta
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - James C Moon
- UCL Institute of Cardiovascular Science, University College London, London, UK
| | - Vikas Kapil
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| | - Amrita Ahluwalia
- William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
| |
Collapse
|
23
|
Taylor RR, Trivedi B, Patel N, Singh R, Ricketts WM, Elliott K, Yarwood M, White V, Hylton H, Allen R, Thomas G, Kapil V, McGuckin R, Pfeffer PE. Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia. Clin Med (Lond) 2021; 21:e384-e391. [PMID: 34103378 DOI: 10.7861/clinmed.2021-0037] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND The COVID-19 pandemic has strained healthcare systems and how best to address post-COVID health needs is uncertain. Here we describe the post-COVID symptoms of 675 patients followed up using a virtual review pathway, stratified by severity of acute COVID infection. METHODS COVID-19 survivors completed an online/telephone questionnaire of symptoms after 12+ weeks and a chest radiograph. Dependent on findings at virtual review, patients were provided information leaflets, attended for investigations and/or were reviewed face-to-face. Outcomes were compared between patients following high-risk and low-risk admissions for COVID pneumonia, and community referrals. RESULTS Patients reviewed after hospitalisation for COVID pneumonia had a median of two ongoing physical health symptoms post-COVID. The most common was fatigue (50.3% of high-risk patients). Symptom burden did not vary significantly by severity of hospitalised COVID pneumonia but was highest in community referrals. Symptoms suggestive of depression, anxiety and post-traumatic stress disorder were common (depression occurred in 24.9% of high-risk patients). Asynchronous virtual review facilitated triage of patients at highest need of face-to-face review. CONCLUSION Many patients continue to have a significant burden of post-COVID symptoms irrespective of severity of initial pneumonia. How best to assess and manage long COVID will be of major importance over the next few years.
Collapse
Affiliation(s)
| | | | | | | | - William M Ricketts
- Barts Health NHS Trust, London, UK, and hon clinical senior lecturer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK
| | | | | | | | | | | | | | - Vikas Kapil
- Barts Health NHS Trust, London, UK, and clinical senior lecturer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK
| | | | - Paul E Pfeffer
- Barts Health NHS Trust, London, UK, and hon senior lecturer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK
| |
Collapse
|
24
|
Crocker-Buque T, Williams S, Brentnall AR, Gabe R, Duffy S, Prowle JR, Orkin C, Kunst H, Cutino-Moguel T, Zenner D, Bloom B, Melzer M, de Freitas S, Darmalingam M, McCafferty K, Kapil V, Pfeffer P, Martin J, Gourtsoyannis Y, Chandran S, Dhariwal A, Rachman R, Milligan I, Mabayoje D, Adobah E, Falconer J, Nugent H, Yaqoob M, Collier D, Pearse R, Caulfield M, Tiberi S. The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London. Int J Tuberc Lung Dis 2021; 25:358-366. [PMID: 33977903 DOI: 10.5588/ijtld.20.0926] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND: Barts Health National Health Service Trust (BHNHST) serves a diverse population of 2.5 million people in London, UK. We undertook a health services assessment of factors used to evaluate the risk of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.METHODS: Patients with confirmed polymerase chain reaction (PCR) test results admitted between 1 March and 1 August 2020 were included, alongwith clinician-diagnosed suspected cases. Prognostic factors from the 4C Mortality score and 4C Deterioration scores were extracted from electronic health records and logistic regression was used to quantify the strength of association with 28-day mortality and clinical deterioration using national death registry linkage.RESULTS: Of 2783 patients, 1621 had a confirmed diagnosis, of whom 61% were male and 54% were from Black and Minority Ethnic groups; 26% died within 28 days of admission. Mortality was strongly associated with older age. The 4C mortality score had good stratification of risk with a calibration slope of 1.14 (95% CI 1.01-1.27). It may have under-estimated mortality risk in those with a high respiratory rate or requiring oxygen.CONCLUSION: Patients in this diverse patient cohort had similar mortality associated with prognostic factors to the 4C score derivation sample, but survival might be poorer in those with respiratory failure.
Collapse
Affiliation(s)
- T Crocker-Buque
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - S Williams
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - A R Brentnall
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK
| | - R Gabe
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK, Barts Clinical Trials Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK
| | - S Duffy
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK
| | - J R Prowle
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK
| | - C Orkin
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK
| | - H Kunst
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK
| | - T Cutino-Moguel
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - D Zenner
- Centre for Global Public Health, Queen Mary University of London, Mile End Road, London, UK
| | - B Bloom
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK
| | - M Melzer
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Whipps Cross University Hospital, Barts Health NHS Trust, Leytonstone, London, UK
| | - S de Freitas
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - M Darmalingam
- Whipps Cross University Hospital, Barts Health NHS Trust, Leytonstone, London, UK
| | - K McCafferty
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - V Kapil
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK, St Bartholomew´s Hospital, Barts Health NHS Trust, West Smithfield, London, UK
| | - P Pfeffer
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK
| | - J Martin
- Newham University Hospital, Barts Health NHS Trust, London, UK
| | - Y Gourtsoyannis
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - S Chandran
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - A Dhariwal
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - R Rachman
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - I Milligan
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - D Mabayoje
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - E Adobah
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - J Falconer
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - H Nugent
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK
| | - M Yaqoob
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK
| | - D Collier
- Barts Clinical Trials Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Mile End Road, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK
| | - R Pearse
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK
| | - M Caulfield
- The William Harvey Research Institute, Queen Mary University of London Charterhouse Square, London, UK
| | - S Tiberi
- The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London, UK, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK, Newham University Hospital, Barts Health NHS Trust, London, UK
| |
Collapse
|
25
|
Alhatali B, Al Lawatia S, Khamis F, Kantur S, Al-Abri S, Kapil V, Thomas J, Johnson R, Hamelin EI, Coleman RM, Kazzi Z. A cluster of tetrodotoxin poisoning in Oman. Clin Toxicol (Phila) 2021; 60:262-266. [PMID: 33913398 DOI: 10.1080/15563650.2021.1917595] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Tetrodotoxin (TTX) is a potent sodium channel blocker, with significant neurotoxicity, found in marine animals like pufferfish and blue-ringed octopus. The severity of toxicity depends on the amount of toxin ingested and the outcome depends on the time-lapse to appropriate medical care. CASES REPORT We report five patients who presented with tetrodotoxin poisoning after consuming fried internal organs of local pufferfish from the coast of Oman. The patients' clinical manifestations were consistent with the expected TTX toxidrome of perioral and generalized paresthesia, weakness of upper and lower extremities, gastrointestinal manifestations, dyspnea, dysarthria, ascending paralysis, hypotension, bradycardia and coma. The severity varied among the patients who recovered completely except one patient who developed a subarachnoid hemorrhage without underlying aneurysms on computed tomography-angiogram. This complication was potentially related to TTX poisoning and has not been previously reported. In addition to standard supportive management, patients with severe illness should potentially receive the intravenous acetylcholinesterase inhibitor neostigmine, and intermittent dialysis. Urine specimens were sent to CDC in Atlanta, where they were analyzed using online solid phase extraction (SPE) with LC-MS/MS and confirmed the diagnosis in all five cases. DISCUSSION In general, the patients' clinical manifestations were consistent with the expected TTX toxidrome except patient 3 who developed a subarachnoid hemorrhage early during his clinical course. Two patients received neostigmine and underwent dialysis with complete recovery.
Collapse
Affiliation(s)
- Badria Alhatali
- Department of Environmental and Occupational Health, Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman
| | | | - Faryal Khamis
- Infectious Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman
| | | | - Seif Al-Abri
- Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman
| | - Vikas Kapil
- Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
| | - Jerry Thomas
- Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Rudolph Johnson
- Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Elizabeth I Hamelin
- Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Rebecca M Coleman
- National Biodefense Analysis and Countermeasures Center, Ft. Detrick, Frederick, MD, USA
| | - Ziad Kazzi
- Emory University School of Medicine, Atlanta, GA, USA
| |
Collapse
|
26
|
Khanji MY, Maniero C, Ng S, Siddiqui I, Gupta J, Crosby L, Antoniou S, Khan R, Kapil V, Gupta A. Early and Mid-Term Implications of the COVID-19 Pandemic on the Physical, Behavioral and Mental Health of Healthcare Professionals: The CoPE-HCP Study Protocol. Front Psychol 2021; 12:616280. [PMID: 33603701 PMCID: PMC7884763 DOI: 10.3389/fpsyg.2021.616280] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Accepted: 01/05/2021] [Indexed: 01/03/2023] Open
Abstract
Introduction The COVID-19 pandemic has led to unprecedented strain to healthcare systems worldwide and posed unique challenges to the healthcare professionals (HCPs) and the general public. Objectives The aim of this study is to evaluate the impact of COVID-19 on the mental health, behavioral, and physical wellbeing of HCPs in the early and mid-term periods of the pandemic in comparison to non-HCPs. Thus, facilitating and guiding optimum planning and delivery of support to HCPs. Methods and Analysis An observational cross-sectional survey and cohort study aiming to enroll over 1050 participants (minimum, 800 HCPs and 250 controls). Study questionnaires will be completed at baseline and after 6-weeks and 4-months. Recruitment initiated July 2020. The study was designed in London, United Kingdom, but open to participants worldwide. Baseline: Questionnaires comprising of validated self-administered screening tools for depression, anxiety, sleep-related issues, wellbeing, and burnout. The questionnaires also explore changes in behavior and physical wellbeing of the participants. In addition, associations of these mental health and behavioral factors with work-related factors and support will be explored. Six-weeks and 4-months follow-up: Follow-up questionnaires will assess change in symptoms of anxiety and depression, sleep disorders, use of alcohol and other substances, behavioral or interpersonal relationship changes. Physical wellbeing will be assessed through the presence of suspected or confirmed COVID-19 infection and absence from work. We will also evaluate the impact of variable provision of personal protection equipment (supply and training), extended working hours, and concern for the wellbeing of family members, anxiety levels, and evidence of burnout. Statistical Considerations The study has 80% power to detect a 10% difference of combined depression and/or anxiety symptoms between the groups using two-sided type 1 error at 0.05 at baseline. Assuming that only 50% of these HCPs agree to be a part of a cohort survey, we will have 80% power to detect around 12% difference in the two groups in reported physical symptoms (20% vs. 32.3%), or prevalence of depression and/or anxiety at the end of the study. Ethics The study was approved by the Cambridge East, Research Ethics Committee (20/EE/0166). Trial Registration Number ClinicalTrials.gov, NCT04433260.
Collapse
Affiliation(s)
- Mohammed Y Khanji
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.,Newham University Hospital, Barts Health NHS Trust, London, United Kingdom.,William Harvey Research Institute, Queen Mary University London, London, United Kingdom
| | - Carmela Maniero
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.,William Harvey Research Institute, Queen Mary University London, London, United Kingdom
| | - Sher Ng
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.,William Harvey Research Institute, Queen Mary University London, London, United Kingdom
| | - Imrana Siddiqui
- Woodgrange Medical Practice, London, United Kingdom.,Wellbeing Hub, Newham Training Hub, London, United Kingdom.,Waltham Forest and East London (WEL) CCGs, London, United Kingdom
| | - Jaya Gupta
- Barnet, Enfield and Haringey Mental Health Trust, London, United Kingdom
| | - Louise Crosby
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.,Newham University Hospital, Barts Health NHS Trust, London, United Kingdom
| | - Sotiris Antoniou
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
| | - Rehan Khan
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
| | - Vikas Kapil
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.,William Harvey Research Institute, Queen Mary University London, London, United Kingdom
| | - Ajay Gupta
- Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.,William Harvey Research Institute, Queen Mary University London, London, United Kingdom
| |
Collapse
|
27
|
Chung R, Tyebally S, Chen D, Kapil V, Walker JM, Addison D, Ismail-Khan R, Guha A, Ghosh AK. Hypertensive Cardiotoxicity in Cancer Treatment-Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies-Epidemiology, Incidence, and Pathophysiology. J Clin Med 2020; 9:jcm9103346. [PMID: 33081013 PMCID: PMC7603211 DOI: 10.3390/jcm9103346] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 10/05/2020] [Accepted: 10/10/2020] [Indexed: 02/07/2023] Open
Abstract
Cardiotoxicity is the umbrella term for cardiovascular side effects of cancer therapies. The most widely recognized phenotype is left ventricular dysfunction, but cardiotoxicity can manifest as arrhythmogenic, vascular, myocarditic and hypertensive toxicities. Hypertension has long been regarded as one of the most prevalent and modifiable cardiovascular risk factors in the general population, but its relevance during the cancer treatment journey may be underestimated. Hypertensive cardiotoxicity occurs de novo in a substantial proportion of treated cancer patients. The pathology is incompletely characterized—natriuresis and renin angiotensin system interactions play a role particularly in conventional treatments, but in novel therapies endothelial dysfunction and the interaction between the cancer and cardiac kinome are implicated. There exists a treatment paradox in that a significant hypertensive response not only mandates anti-hypertensive treatment, but in fact, in certain cancer treatment scenarios, hypertension is a predictor of cancer treatment efficacy and response. In this comprehensive review of over 80,000 patients, we explored the epidemiology, incidence, and mechanistic pathophysiology of hypertensive cardiotoxicity in adjunct, conventional chemotherapy, and novel cancer treatments. Conventional chemotherapy, adjunct treatments, and novel targeted therapies collectively caused new onset hypertension in 33–68% of treated patients. The incidence of hypertensive cardiotoxicity across twenty common novel therapies for any grade hypertension ranged from 4% (imatinib) to 68% (lenvatinib), and high grade 3 or 4 hypertension in <1% (imatinib) to 42% (lenvatinib). The weighted average effect was all-grade hypertension in 24% and grade 3 or 4 hypertension in 8%.
Collapse
Affiliation(s)
- Robin Chung
- Cardio-Oncology Service, Barts Heart Centre, St Bartholomew’s Hospital, London EC1A 7BE, UK; (R.C.); (S.T.); (D.C.)
- Cardio-Oncology Service, University College London Hospital, London WC1E 6HX, UK;
| | - Sara Tyebally
- Cardio-Oncology Service, Barts Heart Centre, St Bartholomew’s Hospital, London EC1A 7BE, UK; (R.C.); (S.T.); (D.C.)
| | - Daniel Chen
- Cardio-Oncology Service, Barts Heart Centre, St Bartholomew’s Hospital, London EC1A 7BE, UK; (R.C.); (S.T.); (D.C.)
- Cardio-Oncology Service, University College London Hospital, London WC1E 6HX, UK;
- Hatter Cardiovascular Institute, University College London, London WC1E 6HX, UK
| | - Vikas Kapil
- Barts Blood Pressure Centre of Excellence, Barts Heart Centre, St Bartholomew’s Hospital, London EC1A 7BE, UK;
- Centre for Cardiovascular Medicine and Devices, NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK
| | - J. Malcolm Walker
- Cardio-Oncology Service, University College London Hospital, London WC1E 6HX, UK;
- Hatter Cardiovascular Institute, University College London, London WC1E 6HX, UK
| | - Daniel Addison
- Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH 43210, USA; (D.A.); (A.G.)
| | - Roohi Ismail-Khan
- Cardio-oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL 33559, USA;
| | - Avirup Guha
- Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH 43210, USA; (D.A.); (A.G.)
- Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, OH 44106, USA
| | - Arjun K Ghosh
- Cardio-Oncology Service, Barts Heart Centre, St Bartholomew’s Hospital, London EC1A 7BE, UK; (R.C.); (S.T.); (D.C.)
- Cardio-Oncology Service, University College London Hospital, London WC1E 6HX, UK;
- Hatter Cardiovascular Institute, University College London, London WC1E 6HX, UK
- Correspondence: ; Tel.: +44-20-7377-7000
| |
Collapse
|
28
|
Augusto JB, Menacho K, Andiapen M, Bowles R, Burton M, Welch S, Bhuva AN, Seraphim A, Pade C, Joy G, Jensen M, Davies RH, Captur G, Fontana M, Montgomery H, O’Brien B, Hingorani AD, Cutino-Moguel T, McKnight Á, Abbass H, Alfarih M, Alldis Z, Baca GL, Boulter A, Bracken OV, Bullock N, Champion N, Chan C, Couto-Parada X, Dieobi-Anene K, Feehan K, Figtree G, Figtree MC, Finlay M, Forooghi N, Gibbons JM, Griffiths P, Hamblin M, Howes L, Itua I, Jones M, Jardim V, Kapil V, Jason Lee WY, Mandadapu V, Mfuko C, Mitchelmore O, Palma S, Patel K, Petersen SE, Piniera B, Raine R, Rapala A, Richards A, Sambile G, Couto de Sousa J, Sugimoto M, Thornton GD, Artico J, Zahedi D, Parker R, Robathan M, Hickling LM, Ntusi N, Semper A, Brooks T, Jones J, Tucker A, Veerapen J, Vijayakumar M, Wodehouse T, Wynne L, Treibel TA, Noursadeghi M, Manisty C, Moon JC. Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Res 2020; 5:179. [PMID: 33537459 PMCID: PMC7836029 DOI: 10.12688/wellcomeopenres.16051.2] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/07/2020] [Indexed: 12/16/2022] Open
Abstract
Background: Most biomedical research has focused on sampling COVID-19 patients presenting to hospital with advanced disease, with less focus on the asymptomatic or paucisymptomatic. We established a bioresource with serial sampling of health care workers (HCWs) designed to obtain samples before and during mainly mild disease, with follow-up sampling to evaluate the quality and duration of immune memory. Methods: We conducted a prospective study on HCWs from three hospital sites in London, initially at a single centre (recruited just prior to first peak community transmission in London), but then extended to multiple sites 3 weeks later (recruitment still ongoing, target n=1,000). Asymptomatic participants attending work complete a health questionnaire, and provide a nasal swab (for SARS-CoV-2 RNA by RT-PCR tests) and blood samples (mononuclear cells, serum, plasma, RNA and DNA are biobanked) at 16 weekly study visits, and at 6 and 12 months. Results: Preliminary baseline results for the first 731 HCWs (400 single-centre, 331 multicentre extension) are presented. Mean age was 38±11 years; 67% are female, 31% nurses, 20% doctors, and 19% work in intensive care units. COVID-19-associated risk factors were: 37% black, Asian or minority ethnicities; 18% smokers; 13% obesity; 11% asthma; 7% hypertension and 2% diabetes mellitus. At baseline, 41% reported symptoms in the preceding 2 weeks. Preliminary test results from the initial cohort (n=400) are available: PCR at baseline for SARS-CoV-2 was positive in 28 of 396 (7.1%, 95% CI 4.9-10.0%) and 15 of 385 (3.9%, 2.4-6.3%) had circulating IgG antibodies. Conclusions: This COVID-19 bioresource established just before the peak of infections in the UK will provide longitudinal assessments of incident infection and immune responses in HCWs through the natural time course of disease and convalescence. The samples and data from this bioresource are available to academic collaborators by application https://covid-consortium.com/application-for-samples/.
Collapse
Affiliation(s)
- João B Augusto
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Katia Menacho
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Mervyn Andiapen
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Ruth Bowles
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Maudrian Burton
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
- NIHR Cardiovascular Biomedical Research Unit, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Sophie Welch
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Anish N Bhuva
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Andreas Seraphim
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Corinna Pade
- William Harvey Research Institute, Queen Mary University of London, London, UK
- The Blizard Institute, Queen Mary University of London School of Medicine and Dentistry, London, UK
| | - George Joy
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Melanie Jensen
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Rhodri H Davies
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Gabriella Captur
- Institute of Cardiovascular Science, University College London, London, UK
- Royal Free London NHS Foundation Trust, London, UK
- MRC Unit for Lifelong Health and Ageing, University College London, London, UK
| | - Marianna Fontana
- Institute of Cardiovascular Science, University College London, London, UK
- Royal Free London NHS Foundation Trust, London, UK
| | - Hugh Montgomery
- Centre for Human Health and Performance, University College London, London, UK
| | - Ben O’Brien
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Aroon D Hingorani
- Institute of Cardiovascular Science, University College London, London, UK
| | | | - Áine McKnight
- The Blizard Institute, Queen Mary University of London School of Medicine and Dentistry, London, UK
| | - Hakam Abbass
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Mashael Alfarih
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Zoe Alldis
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Georgina L Baca
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Alex Boulter
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | | | - Natalie Bullock
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Nicola Champion
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Carmen Chan
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | | | - Keenan Dieobi-Anene
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Karen Feehan
- Division of Medicine, University College London, London, UK
| | - Gemma Figtree
- Royal North Shore Hospital; The University of Sydney, Sydney, Australia
| | - Melanie C Figtree
- Royal North Shore Hospital; The University of Sydney, Sydney, Australia
| | - Malcolm Finlay
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Nasim Forooghi
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Joseph M Gibbons
- The Blizard Institute, Queen Mary University of London School of Medicine and Dentistry, London, UK
| | - Peter Griffiths
- School of Health Sciences, University of Southampton & NIHR Applied Research Collaboration (ARC), Wessex, UK
| | - Matt Hamblin
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Lee Howes
- Institute of Cardiovascular Science, University College London, London, UK
| | - Ivie Itua
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Meleri Jones
- Wolfson Institute of Preventative Medicine, Centre for Cancer Prevention, Queen Mary University of London, London, UK
| | - Victor Jardim
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Vikas Kapil
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Wing-Yiu Jason Lee
- The Blizard Institute, Queen Mary University of London School of Medicine and Dentistry, London, UK
| | - Vineela Mandadapu
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Celina Mfuko
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Oliver Mitchelmore
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Susana Palma
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Kush Patel
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Steffen E Petersen
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
- NIHR Cardiovascular Biomedical Research Unit, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Brian Piniera
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Rosalind Raine
- Department of Applied Health Research, University College London, London, UK
| | - Alicja Rapala
- Institute of Cardiovascular Science, University College London, London, UK
| | - Amy Richards
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Genine Sambile
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Jorge Couto de Sousa
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | | | - George D Thornton
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Jessica Artico
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Dan Zahedi
- School of Clinical Medicine, University of Cambridge, Cambridge, UK
| | - Ruth Parker
- School of Clinical Medicine, University of Cambridge, Cambridge, UK
| | - Mathew Robathan
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Lauren M Hickling
- East London NHS Foundation Trust Unit for Social and Community Psychiatry, Newham Centre for Mental Health, London, UK
| | - Ntobeko Ntusi
- Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | | | | | | | - Art Tucker
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Jessry Veerapen
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Mohit Vijayakumar
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Theresa Wodehouse
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Lucinda Wynne
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Thomas A Treibel
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Mahdad Noursadeghi
- Division of Infection and Immunity, University College London, London, UK
| | - Charlotte Manisty
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - James C Moon
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| |
Collapse
|
29
|
Augusto JB, Menacho K, Andiapen M, Bowles R, Burton M, Welch S, Bhuva AN, Seraphim A, Pade C, Joy G, Jensen M, Davies RH, Captur G, Fontana M, Montgomery H, O’Brien B, Hingorani AD, Cutino-Moguel T, McKnight Á, Abbass H, Alfarih M, Alldis Z, Baca GL, Boulter A, Bracken OV, Bullock N, Champion N, Chan C, Couto-Parada X, Dieobi-Anene K, Feehan K, Figtree G, Figtree MC, Finlay M, Forooghi N, Gibbons JM, Griffiths P, Hamblin M, Howes L, Itua I, Jones M, Jardim V, Kapil V, Jason Lee WY, Mandadapu V, Mfuko C, Mitchelmore O, Palma S, Patel K, Petersen SE, Piniera B, Raine R, Rapala A, Richards A, Sambile G, Couto de Sousa J, Sugimoto M, Thornton GD, Artico J, Zahedi D, Parker R, Robathan M, Hickling LM, Ntusi N, Semper A, Brooks T, Jones J, Tucker A, Veerapen J, Vijayakumar M, Wodehouse T, Wynne L, Treibel TA, Noursadeghi M, Manisty C, Moon JC. Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Res 2020; 5:179. [PMID: 33537459 PMCID: PMC7836029 DOI: 10.12688/wellcomeopenres.16051.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/15/2020] [Indexed: 01/20/2024] Open
Abstract
Background: Most biomedical research has focused on sampling COVID-19 patients presenting to hospital with advanced disease, with less focus on the asymptomatic or paucisymptomatic. We established a bioresource with serial sampling of health care workers (HCWs) designed to obtain samples before and during mainly mild disease, with follow-up sampling to evaluate the quality and duration of immune memory. Methods: We conducted a prospective observational study on HCWs from three hospital sites in London, initially at a single centre (recruited just prior to first peak community transmission in London), but then extended to multiple sites 3 weeks later (recruitment still ongoing, target n=1,000). Asymptomatic participants attending work complete a health questionnaire, and provide a nasal swab (for SARS-CoV-2 RNA by RT-PCR tests) and blood samples (mononuclear cells, serum, plasma, RNA and DNA are biobanked) at 16 weekly study visits, and at 6 and 12 months. Results: Preliminary baseline results for the first 731 HCWs (400 single-centre, 331 multicentre extension) are presented. Mean age was 38±11 years; 67% are female, 31% nurses, 20% doctors, and 19% work in intensive care units. COVID-19-associated risk factors were: 37% black, Asian or minority ethnicities; 18% smokers; 13% obesity; 11% asthma; 7% hypertension and 2% diabetes mellitus. At baseline, 41% reported symptoms in the preceding 2 weeks. Preliminary test results from the initial cohort (n=400) are available: PCR at baseline for SARS-CoV-2 was positive in 28 of 396 (7.1%, 95% CI 4.9-10.0%) and 15 of 385 (3.9%, 2.4-6.3%) had circulating IgG antibodies. Conclusions: This COVID-19 bioresource established just before the peak of infections in the UK will provide longitudinal assessments of incident infection and immune responses in HCWs through the natural time course of disease and convalescence. The samples and data from this bioresource are available to academic collaborators by application https://covid-consortium.com/application-for-samples/.
Collapse
Affiliation(s)
- João B Augusto
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Katia Menacho
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Mervyn Andiapen
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Ruth Bowles
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Maudrian Burton
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
- NIHR Cardiovascular Biomedical Research Unit, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Sophie Welch
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Anish N Bhuva
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Andreas Seraphim
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Corinna Pade
- William Harvey Research Institute, Queen Mary University of London, London, UK
- The Blizard Institute, Queen Mary University of London School of Medicine and Dentistry, London, UK
| | - George Joy
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Melanie Jensen
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Rhodri H Davies
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Gabriella Captur
- Institute of Cardiovascular Science, University College London, London, UK
- Royal Free London NHS Foundation Trust, London, UK
- MRC Unit for Lifelong Health and Ageing, University College London, London, UK
| | - Marianna Fontana
- Institute of Cardiovascular Science, University College London, London, UK
- Royal Free London NHS Foundation Trust, London, UK
| | - Hugh Montgomery
- Centre for Human Health and Performance, University College London, London, UK
| | - Ben O’Brien
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Aroon D Hingorani
- Institute of Cardiovascular Science, University College London, London, UK
| | | | - Áine McKnight
- The Blizard Institute, Queen Mary University of London School of Medicine and Dentistry, London, UK
| | - Hakam Abbass
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Mashael Alfarih
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Zoe Alldis
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Georgina L Baca
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Alex Boulter
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | | | - Natalie Bullock
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Nicola Champion
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Carmen Chan
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | | | - Keenan Dieobi-Anene
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Karen Feehan
- Division of Medicine, University College London, London, UK
| | - Gemma Figtree
- Royal North Shore Hospital; The University of Sydney, Sydney, Australia
| | - Melanie C Figtree
- Royal North Shore Hospital; The University of Sydney, Sydney, Australia
| | - Malcolm Finlay
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Nasim Forooghi
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Joseph M Gibbons
- The Blizard Institute, Queen Mary University of London School of Medicine and Dentistry, London, UK
| | - Peter Griffiths
- School of Health Sciences, University of Southampton & NIHR Applied Research Collaboration (ARC), Wessex, UK
| | - Matt Hamblin
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Lee Howes
- Institute of Cardiovascular Science, University College London, London, UK
| | - Ivie Itua
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Meleri Jones
- Wolfson Institute of Preventative Medicine, Centre for Cancer Prevention, Queen Mary University of London, London, UK
| | - Victor Jardim
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Vikas Kapil
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Wing-Yiu Jason Lee
- The Blizard Institute, Queen Mary University of London School of Medicine and Dentistry, London, UK
| | - Vineela Mandadapu
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Celina Mfuko
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Oliver Mitchelmore
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Susana Palma
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Kush Patel
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Steffen E Petersen
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
- NIHR Cardiovascular Biomedical Research Unit, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Brian Piniera
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Rosalind Raine
- Department of Applied Health Research, University College London, London, UK
| | - Alicja Rapala
- Institute of Cardiovascular Science, University College London, London, UK
| | - Amy Richards
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Genine Sambile
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Jorge Couto de Sousa
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | | | - George D Thornton
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Jessica Artico
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Dan Zahedi
- School of Clinical Medicine, University of Cambridge, Cambridge, UK
| | - Ruth Parker
- School of Clinical Medicine, University of Cambridge, Cambridge, UK
| | - Mathew Robathan
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Lauren M Hickling
- East London NHS Foundation Trust Unit for Social and Community Psychiatry, Newham Centre for Mental Health, London, UK
| | - Ntobeko Ntusi
- Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
| | | | | | | | - Art Tucker
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- William Harvey Research Institute, Queen Mary University of London, London, UK
| | - Jessry Veerapen
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Mohit Vijayakumar
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Theresa Wodehouse
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Lucinda Wynne
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Thomas A Treibel
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - Mahdad Noursadeghi
- Division of Infection and Immunity, University College London, London, UK
| | - Charlotte Manisty
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| | - James C Moon
- Institute of Cardiovascular Science, University College London, London, UK
- Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
| |
Collapse
|
30
|
Ochieng WO, Ye T, Scheel C, Lor A, Saindon J, Yee SL, Meltzer MI, Kapil V, Karem K. Uncrewed aircraft systems versus motorcycles to deliver laboratory samples in west Africa: a comparative economic study. Lancet Glob Health 2020; 8:e143-e151. [PMID: 31839129 DOI: 10.1016/s2214-109x(19)30464-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 10/09/2019] [Accepted: 10/16/2019] [Indexed: 10/25/2022]
Abstract
BACKGROUND Transportation of laboratory samples in low-income and middle-income countries is often constrained by poor road conditions, difficult geographical terrain, and insecurity. These constraints can lead to long turnaround times for laboratory diagnostic tests and hamper epidemic control or patient treatment efforts. Although uncrewed aircraft systems (UAS)-ie, drones-can mitigate some of these transportation constraints, their cost-effectiveness compared with land-based transportation systems is unclear. METHODS We did a comparative economic study of the costs and cost-effectiveness of UAS versus motorcycles in Liberia (west Africa) for transportation of laboratory samples under simulated routine conditions and public health emergency conditions (based on the 2013-16 west African Ebola virus disease epidemic). We modelled three UAS with operational ranges of 30 km, 65 km, and 100 km (UAS30, UAS65, and UAS100) and lifespans of 1000 to 10 000 h, and compared the costs and number of samples transported with an established motorcycle transportation programme (most commonly used by the Liberian Ministry of Health and the charity Riders for Health). Data for UAS were obtained from Skyfire (a UAS consultancy), Vayu (a UAS manufacturer), and Sandia National Laboratories (a private company with UAS research experience). Motorcycle operational data were obtained from Riders for Health. In our model, we included costs for personnel, equipment, maintenance, and training, and did univariate and probabilistic sensitivity analyses for UAS lifespans, range, and accident or failures. FINDINGS Under the routine scenario, the per sample transport costs were US$0·65 (95% CI 0·01-2·85) and $0·82 (0·56-5·05) for motorcycles and UAS65, respectively. Per-sample transport costs under the emergency scenario were $24·06 (95% CI 21·14-28·20) for motorcycles, $27·42 (95% CI 19·25-136·75) for an unadjusted UAS model with insufficient geographical coverage, and $34·09 (95% CI 26·70-127·40) for an adjusted UAS model with complementary motorcycles. Motorcycles were more cost-effective than short-range UAS (ie, UAS30). However, with increasing range and operational lifespans, UAS became increasingly more cost-effective. INTERPRETATION Given the current level of technology, purchase prices, equipment lifespans, and operational flying ranges, UAS are not a viable option for routine transport of laboratory samples in west Africa. Field studies are required to generate evidence about UAS lifespan, failure rates, and performance under different weather conditions and payloads. FUNDING None.
Collapse
Affiliation(s)
- Walter O Ochieng
- Karna LLC, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
| | - Tun Ye
- Office of the Director, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Christina Scheel
- Office of the Director, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Aun Lor
- Office of the Director, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - John Saindon
- Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Sue Lin Yee
- Office of the Director, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Martin I Meltzer
- Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Vikas Kapil
- Office of the Director, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Kevin Karem
- Office of the Director, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|
31
|
Kapil V, Khambata RS, Jones DA, Rathod K, Primus C, Massimo G, Fukuto JM, Ahluwalia A. The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. Pharmacol Rev 2020; 72:692-766. [DOI: 10.1124/pr.120.019240] [Citation(s) in RCA: 69] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
32
|
Gupta AK, Jneid H, Addison D, Ardehali H, Boehme AK, Borgaonkar S, Boulestreau R, Clerkin K, Delarche N, DeVon HA, Grumbach IM, Gutierrez J, Jones DA, Kapil V, Maniero C, Mentias A, Miller PS, Ng SM, Parekh JD, Sanchez RH, Sawicki KT, te Riele ASJM, Remme CA, London B. Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors. J Am Heart Assoc 2020; 9:e017013. [PMID: 32347144 PMCID: PMC7429024 DOI: 10.1161/jaha.120.017013] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 04/28/2020] [Indexed: 01/08/2023]
Abstract
Coronavirus Disease 2019 (COVID-19) has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020. In this White Paper, we address the cardiovascular co-morbidities of COVID-19 infection; the diagnosis and treatment of standard cardiovascular conditions during the pandemic; and the diagnosis and treatment of the cardiovascular consequences of COVID-19 infection. In addition, we will also address various issues related to the safety of healthcare workers and the ethical issues related to patient care in this pandemic.
Collapse
Affiliation(s)
- Ajay K. Gupta
- William Harvey Research InstituteBarts and the London School of Medicine and DentistryQueen Mary University of LondonUnited Kingdom
- Barts BP Centre of ExcellenceBarts Heart CentreLondonUnited Kingdom
- Royal London and St Bartholomew’s HospitalBarts Health NHS TrustLondonUnited Kingdom
| | - Hani Jneid
- Division of CardiologyBaylor College of MedicineHoustonTX
| | - Daniel Addison
- Division of Cardiovascular MedicineDepartment of MedicineThe Ohio State UniversityColumbusOH
| | - Hossein Ardehali
- Feinberg Cardiovascular and Renal Research InstituteNorthwestern UniversityChicagoIL
| | - Amelia K. Boehme
- Department of NeurologyVagelos College of Physicians and SurgeonsColumbia UniversityNew YorkNY
- Department of EpidemiologyMailman School of Public HealthColumbia UniversityNew YorkNY
| | | | | | - Kevin Clerkin
- Division of CardiologyDepartment of MedicineVagelos College of Physicians and SurgeonsColumbia UniversityNew YorkNY
| | | | - Holli A. DeVon
- University of California, Los Angeles, School of NursingLos AngelesCA
| | - Isabella M. Grumbach
- Division of Cardiovascular MedicineDepartment of MedicineUniversity of IowaCarver College of MedicineIowa CityIA
| | - Jose Gutierrez
- Department of NeurologyVagelos College of Physicians and SurgeonsColumbia UniversityNew YorkNY
| | - Daniel A. Jones
- William Harvey Research InstituteBarts and the London School of Medicine and DentistryQueen Mary University of LondonUnited Kingdom
- Royal London and St Bartholomew’s HospitalBarts Health NHS TrustLondonUnited Kingdom
| | - Vikas Kapil
- William Harvey Research InstituteBarts and the London School of Medicine and DentistryQueen Mary University of LondonUnited Kingdom
- Barts BP Centre of ExcellenceBarts Heart CentreLondonUnited Kingdom
| | - Carmela Maniero
- William Harvey Research InstituteBarts and the London School of Medicine and DentistryQueen Mary University of LondonUnited Kingdom
- Barts BP Centre of ExcellenceBarts Heart CentreLondonUnited Kingdom
| | - Amgad Mentias
- Division of CardiologyDepartment of Internal MedicineUniversity of IowaIowa CityIA
| | | | - Sher May Ng
- Royal London and St Bartholomew’s HospitalBarts Health NHS TrustLondonUnited Kingdom
| | - Jai D. Parekh
- Division of Cardiovascular MedicineDepartment of MedicineUniversity of IowaCarver College of MedicineIowa CityIA
| | - Reynaldo H. Sanchez
- Division of Cardiovascular MedicineDepartment of MedicineThe Ohio State UniversityColumbusOH
| | - Konrad Teodor Sawicki
- Feinberg Cardiovascular and Renal Research InstituteNorthwestern UniversityChicagoIL
| | - Anneline S. J. M. te Riele
- Division of Heart and LungsDepartment of CardiologyUniversity Medical Center UtrechtUtrechtthe Netherlands
| | - Carol Ann Remme
- Department of Clinical and Experimental CardiologyHeart CentreAmsterdam UMCLocation Academic Medical CenterAmsterdamthe Netherlands
| | - Barry London
- Division of Cardiovascular MedicineDepartment of MedicineUniversity of IowaCarver College of MedicineIowa CityIA
| |
Collapse
|
33
|
Affiliation(s)
- Vikas Kapil
- Barts Blood Pressure Centre of ExcellenceBarts Heart CentreBarts Health NHS TrustLondonUnited Kingdom
- Centre for Cardiovascular Medicine and Device InnovationWilliam Harvey Research InstituteQueen Mary University LondonLondonUnited Kingdom
| | - Ajay K. Gupta
- Barts Blood Pressure Centre of ExcellenceBarts Heart CentreBarts Health NHS TrustLondonUnited Kingdom
- Centre for Clinical PharmacologyWilliam Harvey Research InstituteQueen Mary University LondonLondonUnited Kingdom
| |
Collapse
|
34
|
Lau CWZ, Hamers AJP, Rathod KS, Shabbir A, Cooper J, Primus CP, Davies C, Mathur A, Moon JC, Kapil V, Ahluwalia A. Randomised, double-blind, placebo-controlled clinical trial investigating the effects of inorganic nitrate in hypertension-induced target organ damage: protocol of the NITRATE-TOD study in the UK. BMJ Open 2020; 10:e034399. [PMID: 31969369 PMCID: PMC7045137 DOI: 10.1136/bmjopen-2019-034399] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
INTRODUCTION Arterial stiffness and left ventricular (LV) hypertrophy are the key markers of hypertensive target organ damage (TOD) associated with increased cardiovascular morbidity and mortality. We have previously shown that dietary inorganic nitrate supplementation lowers blood pressure (BP) in hypertension, however, whether this approach might also improve markers of hypertensive TOD is unknown. In this study, we will investigate whether daily dietary inorganic nitrate administration reduces LV mass and improves measures of arterial stiffness. METHODS AND DESIGN NITRATE-TOD is a double-blind, randomised, single-centre, placebo-controlled phase II trial aiming to enrol 160 patients with suboptimal BP control on one or more antihypertensives. Patients will be randomised to receive 4 months once daily dose of either nitrate-rich beetroot juice or nitrate-deplete beetroot juice (placebo). The primary outcomes are reduction in LV mass and reduction in pulse wave velocity (PWV) and central BP.The study has a power of 95% for detecting a 9 g LV mass change by cardiovascular MRI (~6% change for a mildly hypertrophied heart of 150 g). For PWV, we have a power of >95% for detecting a 0.6 m/s absolute change. For central systolic BP, we have a>90% power to detect a 5.8 mm Hg difference in central systolic BP.Secondary end points include change in ultrasound flow-mediated dilation, change in plasma nitrate and nitrite concentration and change in BP. ETHICS AND DISSEMINATION The study was approved by the London-City and East Research Ethics Committee (10/H0703/98). Trial results will be published according to the Consolidated Standards of Reporting Trials statement and will be presented at conferences and reported in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT03088514.
Collapse
Affiliation(s)
- Clement Wai Zhen Lau
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
- Department of Cardiology, Barts Health NHS Trust, London, UK
| | | | - Krishnaraj Sinhji Rathod
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
- Department of Cardiology, Barts Health NHS Trust, London, UK
| | - Asad Shabbir
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
| | - Jackie Cooper
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
| | - Christopher Peter Primus
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
- Department of Cardiology, Barts Health NHS Trust, London, UK
| | - Ceri Davies
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
- Department of Cardiology, Barts Health NHS Trust, London, UK
| | - Anthony Mathur
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
- Department of Cardiology, Barts Health NHS Trust, London, UK
| | - James C Moon
- Department of Cardiology, Barts Health NHS Trust, London, UK
- UCL Institute of Cardiovascular Science, University College London, London, UK
| | - Vikas Kapil
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
- Department of Cardiology, Barts Health NHS Trust, London, UK
| | - Amrita Ahluwalia
- William Harvey Research Institute, Barts & The London, Queen Mary University of London, London, UK
| |
Collapse
|
35
|
Mowafi H, Ngaruiya C, O'Reilly G, Kobusingye O, Kapil V, Rubiano A, Ong M, Puyana JC, Rahman AF, Jooma R, Beecroft B, Razzak J. Emergency care surveillance and emergency care registries in low-income and middle-income countries: conceptual challenges and future directions for research. BMJ Glob Health 2019; 4:e001442. [PMID: 31406601 PMCID: PMC6666805 DOI: 10.1136/bmjgh-2019-001442] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Revised: 03/13/2019] [Accepted: 03/17/2019] [Indexed: 12/17/2022] Open
Abstract
Despite the fact that the 15 leading causes of global deaths and disability-adjusted life years are from conditions amenable to emergency care, and that this burden is highest in low-income and middle-income countries (LMICs), there is a paucity of research on LMIC emergency care to guide policy making, resource allocation and service provision. A literature review of the 550 articles on LMIC emergency care published in the 10-year period from 2007 to 2016 yielded 106 articles for LMIC emergency care surveillance and registry research. Few articles were from established longitudinal surveillance or registries and primarily composed of short-term data collection. Using these articles, a working group was convened by the US National Institutes of Health Fogarty International Center to discuss challenges and potential solutions for established systems to better understand global emergency care in LMICs. The working group focused on potential uses for emergency care surveillance and registry data to improve the quality of services provided to patients. Challenges included a lack of dedicated resources for such research in LMIC settings as well as over-reliance on facility-based data collection without known correlation to the overall burden of emergency conditions in the broader community. The group outlined potential solutions including incorporating data from sources beyond traditional health records, use of standard clinical forms that embed data needed for research and policy making and structured population-based research to establish clear linkages between what is seen in emergency units and the wider community. The group then identified current gaps in LMIC emergency care surveillance and registry research to form a research agenda for the future.
Collapse
Affiliation(s)
- Hani Mowafi
- Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Christine Ngaruiya
- Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Gerard O'Reilly
- Department of Epidemiology & Preventative Medicine, Monash University, Clayton, Victoria, Australia
| | - Olive Kobusingye
- Department of Disease Control & Environmental Health, Makerere University School of Public Health, Kampala, Uganda
| | - Vikas Kapil
- Center for Global Health Leadership, Centers for Disease Control and Prevention Center for Global Health, Atlanta, Georgia, USA
| | - Andres Rubiano
- Department of Neurosurgery, Universidad El Bosque, Bogota, Comoros
| | - Marcus Ong
- Department of Emergency Medicine, Duke-NUS Medical School, Singapore, Singapore
| | - Juan Carlos Puyana
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | | | - Rashid Jooma
- Department of Neurosurgery, Aga Khan University Medical College Pakistan, Karachi, Sindh, Pakistan
| | - Blythe Beecroft
- CGHS, John E Fogarty International Center, Bethesda, Maryland, USA
| | - Junaid Razzak
- Emergency Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| |
Collapse
|
36
|
Lobo MD, Sharp ASP, Kapil V, Davies J, de Belder MA, Cleveland T, Bent C, Chapman N, Dasgupta I, Levy T, Mathur A, Matson M, Saxena M, Cappuccio FP. Joint UK societies' 2019 consensus statement on renal denervation. Heart 2019; 105:1456-1463. [PMID: 31292190 PMCID: PMC6817707 DOI: 10.1136/heartjnl-2019-315098] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Revised: 04/11/2019] [Accepted: 04/16/2019] [Indexed: 02/06/2023] Open
Abstract
Improved and durable control of hypertension is a global priority for healthcare providers and policymakers. There are several lifestyle measures that are proven to result in improved blood pressure (BP) control. Moreover, there is incontrovertible evidence from large scale randomised controlled trials (RCTs) that antihypertensive drugs lower BP safely and effectively in the long-term resulting in substantial reduction in cardiovascular morbidity and mortality. Importantly, however, evidence is accumulating to suggest that patients neither sustain long-term healthy behaviours nor adhere to lifelong drug treatment regimens and thus alternative measures to control hypertension warrant further investigation. Endovascular renal denervation (RDN) appears to hold some promise as a non-pharmacological approach to lowering BP and achieves renal sympathectomy using either radiofrequency energy or ultrasound-based approaches. This treatment modality has been evaluated in clinical trials in humans since 2009 but initial studies were compromised by being non-randomised, without sham control and small in size. Subsequently, clinical trial design and rigour of execution has been greatly improved resulting in recent sham-controlled RCTs that demonstrate short-term reduction in ambulatory BP without any significant safety concerns in both medication-naïve and medication-treated hypertensive patients. Despite this, the joint UK societies still feel that further evaluation of this therapy is warranted and that RDN should not be offered to patients outside of the context of clinical trials. This document reviews the updated evidence since our last consensus statement from 2014 and provides a research agenda for future clinical studies.
Collapse
Affiliation(s)
- Melvin D Lobo
- William Harvey Research Institute, Centre for Clinical Pharmacology, NIHR Biomedical Research Centre at Barts, Queen Mary University London, London, UK.,Department of Cardiovascular Medicine, Barts Heart Centre, Barts Health NHS Trust, London, UK
| | - Andrew S P Sharp
- Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.,Department of Cardiology, Exeter Hospital, University of Exeter, Exeter, UK
| | - Vikas Kapil
- William Harvey Research Institute, Centre for Clinical Pharmacology, NIHR Biomedical Research Centre at Barts, Queen Mary University London, London, UK.,Department of Cardiovascular Medicine, Barts Heart Centre, Barts Health NHS Trust, London, UK
| | - Justin Davies
- Department of Cardiology, Imperial College Healthcare Trust, London, UK
| | - Mark A de Belder
- Department of Cardiology, James Cook University Hospital, Middlesborough, UK.,The National Institute for Cardiovascular Outcomes Research, Barts Health NHS Trust, London, UK
| | - Trevor Cleveland
- Sheffield Vascular Institute, Sheffield Teaching Hospitals NHSFT, Northern General Hospital, Sheffield, UK
| | - Clare Bent
- Department of Interventional Radiology, The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK
| | - Neil Chapman
- Department of Cardiology, Imperial College Healthcare Trust, London, UK
| | - Indranil Dasgupta
- Department of Renal Medicine, Birmingham Heartlands Hospital, Birmingham, UK
| | - Terry Levy
- Department of Interventional Radiology, The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK
| | - Anthony Mathur
- William Harvey Research Institute, Centre for Clinical Pharmacology, NIHR Biomedical Research Centre at Barts, Queen Mary University London, London, UK.,Department of Cardiovascular Medicine, Barts Heart Centre, Barts Health NHS Trust, London, UK
| | | | - Manish Saxena
- William Harvey Research Institute, Centre for Clinical Pharmacology, NIHR Biomedical Research Centre at Barts, Queen Mary University London, London, UK.,Department of Cardiovascular Medicine, Barts Heart Centre, Barts Health NHS Trust, London, UK
| | - Francesco P Cappuccio
- Warwick Medical School, University of Warwick, Coventry, UK.,University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK
| | | |
Collapse
|
37
|
Kapil V, Rathod KS, Khambata RS, Bahra M, Velmurugan S, Purba A, S Watson D, Barnes MR, Wade WG, Ahluwalia A. Sex differences in the nitrate-nitrite-NO • pathway: Role of oral nitrate-reducing bacteria. Free Radic Biol Med 2018; 126:113-121. [PMID: 30031863 DOI: 10.1016/j.freeradbiomed.2018.07.010] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 06/15/2018] [Accepted: 07/18/2018] [Indexed: 01/22/2023]
Abstract
Oral reduction of nitrate to nitrite is dependent on the oral microbiome and is the first step of an alternative mammalian pathway to produce nitric oxide in humans. Preliminary evidence suggests important sex differences in this pathway. We prospectively investigated sex-differences following inorganic nitrate supplementation on nitrate/nitrite levels and vascular function, and separately examined sex differences in oral nitrate reduction, and oral microbiota by 16S rRNA profiling. At baseline, females exhibit higher nitrite levels in all biological matrices despite similar nitrate levels to males. Following inorganic nitrate supplementation, plasma nitrite was increased to a significantly greater extent in females than in males and pulse wave velocity was only reduced in females. Females exhibited higher oral bacterial nitrate-reducing activity at baseline and after nitrate supplementation. Despite these differences, there were no differences in the composition of either the total salivary microbiota or those oral taxa with nitrate reductase genes. Our results demonstrate that females have augmented oral nitrate reduction that contributes to higher nitrite levels at baseline and also after inorganic nitrate supplementation, however this was not associated with differences in microbial composition (clinicaltrials.gov: NCT01583803).
Collapse
Affiliation(s)
- Vikas Kapil
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Krishnaraj S Rathod
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Rayomand S Khambata
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Manpreet Bahra
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Shanti Velmurugan
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Amandeep Purba
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - David S Watson
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Michael R Barnes
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - William G Wade
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Newark Street, London E1 2AT, UK
| | - Amrita Ahluwalia
- William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
| |
Collapse
|
38
|
Drużbicki K, Krzystyniak M, Hollas D, Kapil V, Slavíček P, Romanelli G, Fernandez-Alonso F. Hydrogen dynamics in solid formic acid: insights from simulations with quantum colored-noise thermostats. ACTA ACUST UNITED AC 2018. [DOI: 10.1088/1742-6596/1055/1/012003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
39
|
Saxena M, Shour T, Shah M, Wolff CB, Julu POO, Kapil V, Collier DJ, Ng FL, Gupta A, Balawon A, Pheby J, Zak A, Rull G, O'Brien B, Schmieder RE, Lobo MD. Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. J Am Heart Assoc 2018; 7:JAHA.118.009151. [PMID: 29895590 PMCID: PMC6220552 DOI: 10.1161/jaha.118.009151] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
BACKGROUND Renal denervation has no validated marker of procedural success. We hypothesized that successful renal denervation would reduce renal sympathetic nerve signaling demonstrated by attenuation of α-1-adrenoceptor-mediated autotransfusion during the Valsalva maneuver. METHODS AND RESULTS In this substudy of the Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension, we enrolled 23 subjects with resistant hypertension. They were randomized either to bilateral renal denervation using therapeutic levels of ultrasound energy (n=12) or sham application of diagnostic ultrasound (n=11). Within-group changes in autonomic parameters, office and ambulatory blood pressure were compared between baseline and 6 months in a double-blind manner. There was significant office blood pressure reduction in both treatment (16.1±27.3 mm Hg, P<0.05) and sham groups (27.9±15.0 mm Hg, P<0.01) because of which the study was discontinued prematurely. However, during the late phase II (Iii) of Valsalva maneuver, renal denervation resulted in substantial and significant reduction in mean arterial pressure (21.8±25.2 mm Hg, P<0.05) with no significant changes in the sham group. Moreover, there were significant reductions in heart rate in the actively treated group at rest (6.0±11.5 beats per minute, P<0.05) and during postural changes (supine 7.2±8.4 beats per minute, P<0.05, sit up 12.7±16.7 beats per minute, P<0.05), which were not observed in the sham group. CONCLUSIONS Blood pressure reduction per se is not necessarily a marker of successful renal nerve ablation. Reduction in splanchnic autotransfusion following renal denervation has not been previously demonstrated and denotes attenuation of (renal) sympathetic efferent activity and could serve as a marker of procedural success. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT02029885.
Collapse
Affiliation(s)
- Manish Saxena
- Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom .,William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Tariq Shour
- Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.,William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Mussadiq Shah
- William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Christopher B Wolff
- William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Peter O O Julu
- William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Vikas Kapil
- Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.,William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - David J Collier
- William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Fu Liang Ng
- Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.,William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Ajay Gupta
- Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.,William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Armida Balawon
- William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Jane Pheby
- William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Anne Zak
- William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Gurvinder Rull
- Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom
| | - Benjamin O'Brien
- William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| | - Roland E Schmieder
- Department of Nephrology and Hypertension, University Hospital, University of Erlangen/Nuremberg, Erlangen, Germany
| | - Melvin D Lobo
- Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.,William Harvey Research Institute, Centre for Clinical Pharmacology, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University London, London, United Kingdom
| |
Collapse
|
40
|
Todd Milne G, Sandner P, Lincoln KA, Harrison PC, Chen H, Wang H, Clifford H, Qian HS, Wong D, Sarko C, Fryer R, Richman J, Reinhart GA, Boustany CM, Pullen SS, Andresen H, Moltzau LR, Cataliotti A, Levy FO, Lukowski R, Frankenreiter S, Friebe A, Calamaras T, Baumgartner R, McLaughlin A, Aronovitz M, Baur W, Wang GR, Kapur N, Karas R, Blanton R, Hell S, Waldman SA, Lin JE, Colon-Gonzalez F, Kim GW, Blomain ES, Merlino D, Snook A, Erdmann J, Wobst J, Kessler T, Schunkert H, Walter U, Pagel O, Walter E, Gambaryan S, Smolenski A, Jurk K, Zahedi R, Klinger JR, Benza RL, Corris PA, Langleben D, Naeije R, Simonneau G, Meier C, Colorado P, Chang MK, Busse D, Hoeper MM, Masferrer JL, Jacobson S, Liu G, Sarno R, Bernier S, Zhang P, Todd Milne G, Flores-Costa R, Currie M, Hall K, Möhrle D, Reimann K, Wolter S, Wolters M, Mergia E, Eichert N, Geisler HS, Ruth P, Friebe A, Feil R, Zimmermann U, Koesling D, Knipper M, Rüttiger L, Tanaka Y, Okamoto A, Nojiri T, Kumazoe M, Tokudome T, Miura K, Hino J, Hosoda H, Miyazato M, Kangawa K, Kapil V, Ahluwalia A, Paolocci N, Eaton P, Campbell JC, Henning P, Franz E, Sankaran B, Herberg FW, Kim C, Wittwer M, Luo Q, Kaila V, Dames SA, Tobin A, Alam M, Rudyk O, Krasemann S, Hartmann K, Prysyazhna O, Zhang M, Zhao L, Weiss A, Schermuly R, Eaton P, Moyes AJ, Chu SM, Baliga RS, Hobbs AJ, Michalakis S, Mühlfriedel R, Schön C, Fischer DM, Wilhelm B, Zobor D, Kohl S, Peters T, Zrenner E, Bartz-Schmidt KU, Ueffing M, Wissinger B, Seeliger M, Biel M, Ranek MJ, Kokkonen KM, Lee DI, Holewinski RJ, Agrawal V, Virus C, Stevens DA, Sasaki M, Zhang H, Mannion MM, Rainer PP, Page RC, Schisler JC, Van Eyk JE, Willis MS, Kass DA, Zaccolo M, Russwurm M, Giesen J, Russwurm C, Füchtbauer EM, Koesling D, Bork NI, Nikolaev VO, Agulló L, Floor M, Villà-Freixa J, Manfra O, Calamera G, Surdo NC, Meier S, Froese A, Nikolaev VO, Zaccolo M, Levy FO, Andressen KW, Aue A, Schwiering F, Groneberg D, Friebe A, Bajraktari G, Burhenne J, Haefeli WE, Weiss J, Beck K, Voussen B, Vincent A, Parsons SP, Huizinga JD, Friebe A, Mónica FZ, Seto E, Murad F, Bian K, Burgoyne JR, Prysyazhna O, Richards D, Eaton P, Calamera G, Bjørnerem M, Ulsund AH, Kim JJ, Kim C, Levy FO, Andressen KW, Donzelli S, Goetz M, Schmidt K, Wolters M, Stathopoulou K, Prysyazhna O, Scotcher J, Dees C, Subramanian H, Butt E, Kamynina A, Bruce King S, Nikolaev VO, de Witt C, Leichert LI, Feil R, Eaton P, Cuello F, Dobrowinski H, Lehners M, Schmidt MPH, Feil R, Feil S, Wen L, Wolters M, Thunemann M, Schmidt K, Olbrich M, Langer H, Gawaz M, Friebe A, de Wit C, Feil R, Franz E, Kim JJ, Bertinetti D, Kim C, Herberg FW, Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Frey R, Humbert M, Groneberg D, Aue A, Schwiering F, Friebe A, Harloff M, Reinders J, Schlossmann J, Jung J, Wales JA, Chen CY, Breci L, Weichsel A, Bernier SG, Solinga R, Sheppeck JE, Renhowe PA, Montfort WR, Qin L, Sung YJ, Casteel D, Kim C, Kollau A, Neubauer A, Schrammel A, Russwurm M, Koesling D, Mayer B, Kumazoe M, Takai M, Takeuchi C, Kadomatsu M, Hiroi S, Takamatsu K, Nojiri T, Kangawa K, Tachibana H, Opelt M, Eroglu E, Waldeck-Weiermair M, Russwurm M, Koesling D, Malli R, Graier WF, Fassett JT, Schrammel A, Mayer B, Sollie SJ, Moltzau LR, Hernandez-Valladares M, Berven F, Levy FO, Andressen KW, Nojiri T, Tokudome T, Kumazoe M, Arai M, Suzuki Y, Miura K, Hino J, Hosoda H, Miyazato M, Okumura M, Kawaoka S, Kangawa K, Peters S, Schmidt H, Selin Kenet B, Nies SH, Frank K, Wen L, Rathjen FG, Feil R, Petrova ON, Lamarre I, Négrerie M, Robinson JW, Egbert JR, Davydova J, Jaffe LA, Potter LR, Robinson JW, Blixt N, Shuhaibar LC, Warren GL, Mansky KC, Jaffe LA, Potter LR, Romoli S, Bauch T, Dröbner K, Eitner F, Ruppert M, Radovits T, Korkmaz-Icöz S, Li S, Hegedűs P, Loganathan S, Németh BT, Oláh A, Mátyás C, Benke K, Merkely B, Karck M, Szabó G, Scheib U, Broser M, Mukherjee S, Stehfest K, Gee CE, Körschen HG, Oertner TG, Hegemann P, Schmidt H, Dickey DM, Dumoulin A, Kühn R, Jaffe L, Potter LR, Rathjen FG, Schobesberger S, Wright P, Poulet C, Mansfield C, Friebe A, Harding SE, Nikolaev VO, Gorelik J, Kollau A, Opelt M, Wölkart G, Gorren ACF, Russwurm M, Koesling D, Schrammel A, Mayer B, Schwaerzer GK, Casteel DE, Dalton ND, Gu Y, Zhuang S, Milewicz DM, Peterson KL, Pilz R, Schwiering F, Aue A, Groneberg D, Friebe A, Argyriou AI, Makrynitsa G, Alexandropoulos II, Stamopoulou A, Bantzi M, Giannis A, Topouzis S, Papapetropoulos A, Spyroulias GA, Stuehr DJ, Ghosh A, Dai Y, Misra S, Tchernychev B, Jung J, Liu G, Silos-Santiago I, Hannig G, Dao VTV, Deile M, Nedvetsky PI, Güldner A, Ibarra-Alvarado C, Gödecke A, Schmidt HHHW, Vachaviolos A, Gerling A, Thunemann M, Lutz SZ, Häring HU, Krüger MA, Pichler BJ, Shipston MJ, Feil S, Feil R, Vandenwijngaert S, Ledsky CD, Agha O, Hu D, Domian IJ, Buys ES, Newton-Cheh C, Bloch DB, Voussen B, Beck K, Mauro N, Keppler J, Friebe A, Ferreira WA, Chweih H, Brito PL, Almeida CB, Penteado CFF, Saad SSO, Costa FF, Frenette PS, Brockschnieder D, Stasch JP, Sandner P, Conran N, Zimmer DP, Tobin J, Shea C, Sarno R, Long K, Jacobson S, Tang K, Germano P, Wakefield J, Banijamali A, Im GYJ, Sheppeck JE, Profy AT, Todd Milne G, Currie MG, Masferrer JL. Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications : Bamberg, Germany. 23-25 June, 2017. BMC Pharmacol Toxicol 2017; 18:64. [PMID: 29035170 PMCID: PMC5667593 DOI: 10.1186/s40360-017-0170-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
41
|
Yip F, Christensen B, Sircar K, Naeher L, Bruce N, Pennise D, Lozier M, Pilishvili T, Loo Farrar J, Stanistreet D, Nyagol R, Muoki J, de Beer L, Sage M, Kapil V. Assessment of traditional and improved stove use on household air pollution and personal exposures in rural western Kenya. Environ Int 2017; 99:185-191. [PMID: 27923586 PMCID: PMC5538771 DOI: 10.1016/j.envint.2016.11.015] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Revised: 09/25/2016] [Accepted: 11/14/2016] [Indexed: 05/19/2023]
Abstract
BACKGROUND Over 40% of the world's population relies on solid fuels for heating and cooking. Use of improved biomass cookstoves (ICS) has the potential to reduce household air pollution (HAP). OBJECTIVES As part of an evaluation to identify ICS for use in Kenya, we collected indoor air and personal air samples to assess differences between traditional cookstoves (TCS) and ICS. METHODS We conducted a cross-over study in 2012 in two Kenyan villages; up to six different ICS were installed in 45 households during six two-week periods. Forty-eight hour kitchen measurements of fine particulate matter (PM2.5) and carbon monoxide (CO) were collected for the TCS and ICS. Concurrent personal CO measurements were conducted on the mother and one child in each household. We performed descriptive analysis and compared paired measurements between baseline (TCS only) and each ICS. RESULTS The geometric mean of 48-hour baseline PM2.5 and CO concentrations in the kitchen was 586μg/m3 (95% CI: 460, 747) and 4.9ppm (95% CI: 4.3, 5.5), respectively. For each ICS, the geometric mean kitchen air pollutant concentration was lower than the TCS: median reductions were 38.8% (95% CI: 29.5, 45.2) for PM2.5 and 27.1% (95% CI: 17.4, 40.3) for CO, with statistically significant relationships for four ICS. We also observed a reduction in personal exposures to CO with ICS use. CONCLUSIONS We observed a reduction in mean 48-hour PM2.5 and CO concentrations compared to the TCS; however, concentrations for both pollutants were still consistently higher than WHO air quality guidelines. Our findings illustrate that ICS tested in real-world settings can reduce exposures to HAP, but implementation of cleaner fuels and related stove technologies may also be necessary to optimize public health benefits.
Collapse
Affiliation(s)
- Fuyuen Yip
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States.
| | - Bryan Christensen
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Kanta Sircar
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Luke Naeher
- Department of Environmental Health Science, College of Public Health, University of Georgia, Athens, GA, United States
| | - Nigel Bruce
- Department of Public Health and Policy, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom
| | - David Pennise
- Berkeley Air Monitoring Group, Berkeley, CA, United States
| | - Matthew Lozier
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Tamara Pilishvili
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Jennifer Loo Farrar
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Debbi Stanistreet
- Department of Public Health and Policy, Institute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom
| | - Ronald Nyagol
- Nyando Integrated Child Health and Education Project/Safe Water and AIDS Project, Kisumu, Kenya
| | - Justus Muoki
- Berkeley Air Monitoring Group, Berkeley, CA, United States
| | - Lindsey de Beer
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Michael Sage
- National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Vikas Kapil
- Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
| |
Collapse
|
42
|
Rathod KS, Kapil V, Velmurugan S, Khambata RS, Siddique U, Khan S, Van Eijl S, Gee LC, Bansal J, Pitrola K, Shaw C, D’Acquisto F, Colas RA, Marelli-Berg F, Dalli J, Ahluwalia A. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J Clin Invest 2017; 127:169-182. [PMID: 27893465 PMCID: PMC5199722 DOI: 10.1172/jci89429] [Citation(s) in RCA: 105] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 10/17/2016] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Cardiovascular disease occurs at lower incidence in premenopausal females compared with age-matched males. This variation may be linked to sex differences in inflammation. We prospectively investigated whether inflammation and components of the inflammatory response are altered in females compared with males. METHODS We performed 2 clinical studies in healthy volunteers. In 12 men and 12 women, we assessed systemic inflammatory markers and vascular function using brachial artery flow-mediated dilation (FMD). In a further 8 volunteers of each sex, we assessed FMD response to glyceryl trinitrate (GTN) at baseline and at 8 hours and 32 hours after typhoid vaccine. In a separate study in 16 men and 16 women, we measured inflammatory exudate mediators and cellular recruitment in cantharidin-induced skin blisters at 24 and 72 hours. RESULTS Typhoid vaccine induced mild systemic inflammation at 8 hours, reflected by increased white cell count in both sexes. Although neutrophil numbers at baseline and 8 hours were greater in females, the neutrophils were less activated. Systemic inflammation caused a decrease in FMD in males, but an increase in females, at 8 hours. In contrast, GTN response was not altered in either sex after vaccine. At 24 hours, cantharidin formed blisters of similar volume in both sexes; however, at 72 hours, blisters had only resolved in females. Monocyte and leukocyte counts were reduced, and the activation state of all major leukocytes was lower, in blisters of females. This was associated with enhanced levels of the resolving lipids, particularly D-resolvin. CONCLUSIONS Our findings suggest that female sex protects against systemic inflammation-induced endothelial dysfunction. This effect is likely due to accelerated resolution of inflammation compared with males, specifically via neutrophils, mediated by an elevation of the D-resolvin pathway. TRIAL REGISTRATION ClinicalTrials.gov NCT01582321 and NRES: City Road and Hampstead Ethics Committee: 11/LO/2038. FUNDING The authors were funded by multiple sources, including the National Institute for Health Research, the British Heart Foundation, and the European Research Council.
Collapse
|
43
|
Rathod KS, Jones DA, Van-Eijl TJA, Tsang H, Warren H, Hamshere SM, Kapil V, Jain AK, Deaner A, Poulter N, Caulfield MJ, Mathur A, Ahluwalia A. Randomised, double-blind, placebo-controlled study investigating the effects of inorganic nitrate on vascular function, platelet reactivity and restenosis in stable angina: protocol of the NITRATE-OCT study. BMJ Open 2016; 6:e012728. [PMID: 27998900 PMCID: PMC5223652 DOI: 10.1136/bmjopen-2016-012728] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
INTRODUCTION The mainstay treatment for reducing the symptoms of angina and long-term risk of heart attacks in patients with heart disease is stent implantation in the diseased coronary artery. While this procedure has revolutionised treatment, the incidence of secondary events remains a concern. These repeat events are thought to be due, in part, to continued enhanced platelet reactivity, endothelial dysfunction and ultimately restenosis of the stented artery. In this study, we will investigate whether a once a day inorganic nitrate administration might favourably modulate platelet reactivity and endothelial function leading to a decrease in restenosis. METHODS AND DESIGN NITRATE-OCT is a double-blind, randomised, single-centre, placebo-controlled phase II trial that will enrol 246 patients with stable angina due to have elective percutaneous coronary intervention procedure with stent implantation. Patients will be randomised to receive 6 months of a once a day dose of either nitrate-rich beetroot juice or nitrate-deplete beetroot juice (placebo) starting up to 1 week before their procedure. The primary outcome is reduction of in-stent late loss assessed by quantitative coronary angiography and optical coherence tomography at 6 months. The study is powered to detect a 0.22±0.55 mm reduction in late loss in the treatment group compared with the placebo group. Secondary end points include change from baseline assessment of endothelial function measured using flow-mediated dilation at 6 months, target vessel revascularisation (TVR), restenosis rate (diameter>50%) and in-segment late loss at 6 months, markers of inflammation and platelet reactivity and major adverse cardiac events (ie, myocardial infarction, death, cerebrovascular accident, TVR) at 12 and 24 months. ETHICS AND DISSEMINATION The study was approved by the Local Ethics Committee (15/LO/0555). Trial results will be published according to the CONSORT statement and will be presented at conferences and reported in peer-reviewed journals. TRIAL REGISTRATION NUMBERS NCT02529189 and ISRCTN17373946, Pre-results.
Collapse
Affiliation(s)
- Krishnaraj S Rathod
- Barts NIHR Cardiovascular Biomedical Research Unit, Centre of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK
- Department of Cardiology, Barts Heart Centre,2 St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Daniel A Jones
- Barts NIHR Cardiovascular Biomedical Research Unit, Centre of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK
- Department of Cardiology, Barts Heart Centre,2 St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - T J A Van-Eijl
- Department of Cardiology, Barts Heart Centre,2 St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Hilda Tsang
- Imperial Clinical Trials Unit, Imperial College, London, UK
| | - Helen Warren
- Barts NIHR Cardiovascular Biomedical Research Unit, Centre of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK
| | - Stephen M Hamshere
- Department of Cardiology, Barts Heart Centre,2 St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Vikas Kapil
- Barts NIHR Cardiovascular Biomedical Research Unit, Centre of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK
| | - Ajay K Jain
- Department of Cardiology, Barts Heart Centre,2 St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
- King George Hospital, Barking and Havering NHS Trust, London, UK
| | - Andrew Deaner
- Department of Cardiology, Barts Heart Centre,2 St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
- King George Hospital, Barking and Havering NHS Trust, London, UK
| | - Neil Poulter
- Imperial Clinical Trials Unit, Imperial College, London, UK
| | - Mark J Caulfield
- Barts NIHR Cardiovascular Biomedical Research Unit, Centre of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK
| | - Anthony Mathur
- Barts NIHR Cardiovascular Biomedical Research Unit, Centre of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK
- Department of Cardiology, Barts Heart Centre,2 St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Amrita Ahluwalia
- Barts NIHR Cardiovascular Biomedical Research Unit, Centre of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK
| |
Collapse
|
44
|
Kapil V, VandeVondele J, Ceriotti M. Accurate molecular dynamics and nuclear quantum effects at low cost by multiple steps in real and imaginary time: Using density functional theory to accelerate wavefunction methods. J Chem Phys 2016; 144:054111. [DOI: 10.1063/1.4941091] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- V. Kapil
- Laboratory of Computational Science and Modelling, Institute of Materials, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - J. VandeVondele
- Department of Materials, ETH Zurich, Wolfgang-Pauli-Strasse 27, CH-8093 Zurich, Switzerland
| | - M. Ceriotti
- Laboratory of Computational Science and Modelling, Institute of Materials, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| |
Collapse
|
45
|
Wolff CB, Collier DJ, Shah M, Saxena M, Brier TJ, Kapil V, Green D, Lobo M. A Discussion on the Regulation of Blood Flow and Pressure. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2016; 876:129-135. [PMID: 26782204 DOI: 10.1007/978-1-4939-3023-4_16] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Affiliation(s)
- Christopher B Wolff
- Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Centre for Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UK.
| | - David J Collier
- Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Centre for Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UK
| | - Mussadiq Shah
- Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Centre for Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UK
| | - Manish Saxena
- Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Centre for Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UK
| | - Timothy J Brier
- Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Centre for Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UK
| | - Vikas Kapil
- Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Centre for Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UK
- Barts BP Clinic, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - David Green
- Anaesthetics Department, King's College School of Medicine and Dentistry, London, UK
| | - Melvin Lobo
- Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Centre for Clinical Pharmacology, William Harvey Heart Centre, Queen Mary University of London, London, UK
- Barts BP Clinic, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| |
Collapse
|
46
|
Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol 2015; 78:190-1. [PMID: 25083536 DOI: 10.1111/bcp.12277] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
47
|
Kapil V, Sobotka PA, Saxena M, Mathur A, Knight C, Dolan E, Stanton A, Lobo MD. Central iliac arteriovenous anastomosis for hypertension: targeting mechanical aspects of the circulation. Curr Hypertens Rep 2015; 17:585. [PMID: 26228235 PMCID: PMC4521087 DOI: 10.1007/s11906-015-0585-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Raised blood pressure is the leading attributable risk factor for global morbidity and mortality. Real world data demonstrates that half of treated patients are at elevated cardiovascular risk because of inadequately controlled BP. In addition to pharmacotherapy, certain interventional strategies to reduce blood pressure and cardiovascular risk in hypertension can be considered according to international guidelines. One of the newer technologies entering this field is a proprietary arteriovenous coupler device that forms a fixed flow arteriovenous conduit in the central vasculature. In this review, we examine the development of and rationale for the creation of a central arteriovenous anastomosis in patients with hypertension and review the proposed mechanisms by which it may ameliorate hypertension. We critically review the clinical trial evidence base to date and postulate on future therapeutic directions.
Collapse
Affiliation(s)
- Vikas Kapil
- />Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew’s Hospital, W Smithfield, London, EC1A 7BE UK
- />William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Charterhouse Square, Queen Mary University London, London, EC1M 6BQ UK
| | - Paul A. Sobotka
- />Department of Internal Medicine, Division of Cardiovascular Diseases, The Ohio State University, Columbus, OH 43210 USA
- />ROX Medical, 150 Calle Iglesia # A, San Clemente, CA 92672 USA
| | - Manish Saxena
- />Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew’s Hospital, W Smithfield, London, EC1A 7BE UK
- />William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Charterhouse Square, Queen Mary University London, London, EC1M 6BQ UK
| | - Anthony Mathur
- />Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew’s Hospital, W Smithfield, London, EC1A 7BE UK
- />Department of Cardiology, Barts Heart Centre, St Bartholomew’s Hospital, W Smithfield, London, EC1A 7BE UK
| | - Charles Knight
- />Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew’s Hospital, W Smithfield, London, EC1A 7BE UK
- />Department of Cardiology, Barts Heart Centre, St Bartholomew’s Hospital, W Smithfield, London, EC1A 7BE UK
| | - Eamon Dolan
- />Department of Medicine for the Elderly, Connolly Hospital, Mill Road, Blanchardstown, Dublin 15 Dublin, Ireland
| | - Alice Stanton
- />Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland Medical School, 123 Saint Stephen’s Green, Dublin 2 Dublin, Ireland
| | - Melvin D. Lobo
- />Barts BP Centre of Excellence, Barts Heart Centre, St Bartholomew’s Hospital, W Smithfield, London, EC1A 7BE UK
- />William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Charterhouse Square, Queen Mary University London, London, EC1M 6BQ UK
| |
Collapse
|
48
|
Antoniou S, Saxena M, Hamedi N, de Cates C, Moghul S, Lidder S, Kapil V, Lobo MD. Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm. J Clin Hypertens (Greenwich) 2015; 18:129-38. [PMID: 26306794 PMCID: PMC5049677 DOI: 10.1111/jch.12637] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 06/18/2015] [Accepted: 06/27/2015] [Indexed: 02/05/2023]
Abstract
Multiple drug intolerance to antihypertensive medications (MDI-HTN) is an overlooked cause of nonadherence. In this study, 55 patients with MDI-HTN were managed with a novel treatment algorithm utilizing sequentially initiated monotherapies or combinations of maximally tolerated doses of fractional tablet doses, liquid formulations, transdermal preparations, and off-label tablet medications. A total of 10% of referred patients had MDI-HTN, resulting in insufficient pharmacotherapy and baseline office blood pressure (OBP) of 178±24/94±15 mm Hg. At baseline, patients were intolerant to 7.6±3.6 antihypertensives; they were receiving 1.4±1.1 medications. After 6 months on the novel MDI-HTN treatment algorithm, both OBP and home blood pressure (HBP) were significantly reduced, with patients receiving 2.0±1.2 medications. At 12 months, OBP was reduced from baseline by 17±5/9±3 mm Hg (P<.01, P<.05) and HBP was reduced by 11±5/12±3 mm Hg (P<.01 for both) while patients were receiving 1.9±1.1 medications. Application of a stratified medicine approach allowed patients to tolerate increased numbers of medications and achieved significant long-term lowering of blood pressure.
Collapse
Affiliation(s)
- Sotiris Antoniou
- Barts BP Centre of Excellence, Barts Heart Centre, Barts Health NHS Trust, London, UK.,Department of Pharmacy, Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Manish Saxena
- Barts BP Centre of Excellence, Barts Heart Centre, Barts Health NHS Trust, London, UK.,William Harvey Research Institute, Centre for Clinical Pharmacology, NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, London, UK
| | - Nadya Hamedi
- Department of Pharmacy, Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - Catherine de Cates
- Barts BP Centre of Excellence, Barts Heart Centre, Barts Health NHS Trust, London, UK
| | - Sakib Moghul
- Barts BP Centre of Excellence, Barts Heart Centre, Barts Health NHS Trust, London, UK
| | - Satnam Lidder
- Barts BP Centre of Excellence, Barts Heart Centre, Barts Health NHS Trust, London, UK
| | - Vikas Kapil
- Barts BP Centre of Excellence, Barts Heart Centre, Barts Health NHS Trust, London, UK.,William Harvey Research Institute, Centre for Clinical Pharmacology, NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, London, UK
| | - Melvin D Lobo
- Barts BP Centre of Excellence, Barts Heart Centre, Barts Health NHS Trust, London, UK.,William Harvey Research Institute, Centre for Clinical Pharmacology, NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, London, UK
| |
Collapse
|
49
|
Velmurugan S, Kapil V, Ghosh SM, Davies S, McKnight A, Aboud Z, Khambata RS, Webb AJ, Poole A, Ahluwalia A. Erratum to "Antiplatelet effects of dietary nitrate in healthy volunteers: Involvement of cGMP and influence of sex" [Free Radic. Biol. Med. 65 (2013) 1521-1532]. Free Radic Biol Med 2015; 84:385. [PMID: 28830618 PMCID: PMC5597546 DOI: 10.1016/j.freeradbiomed.2015.03.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Shanti Velmurugan
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ
| | - Vikas Kapil
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ
| | - Suborno M Ghosh
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ
| | - Sheridan Davies
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ
| | - Andrew McKnight
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ
| | - Zainab Aboud
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ
| | - Rayomand S Khambata
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ
| | - Andrew J Webb
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ
| | - Alastair Poole
- School of Physiology and Pharmacology, University of Bristol, Medical Sciences Building, University Walk, Bristol BS8 1TD, UK
| | - Amrita Ahluwalia
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts NIHR Cardiovascular Biomedical Research Unit, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ.
| |
Collapse
|
50
|
Antoniou S, Hamedi N, Lidder S, Saxena M, Brier T, Robinson P, Kapil V, Lobo M. CP-081 Management of uncontrolled blood pressure in patients with multiple drug intolerance referred to a specialist hypertension clinic: Abstract CP-081 Table 1. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|